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Previous research into post-operative antibiotic usage for chronic rhinosinusitis (CRS) patients 
generated contradictory results. Some studies found that post-operative antibiotics did not 
improve the short-term clinical outcomes (Jiang et al., 2008; Lehmann et al., 2020; Liang et 
al., 2011) while some did (Albu & Lucaciu, 2010). Those studies had also focused primarily 
on the clinical outcomes of the surgery, overlooking the potential impact of prophylactic 
antibiotics on the sinonasal microbiome. Using cultivation-independent methods, this study 
aimed to examine the impact of post-operative antibiotics on the sinonasal microbiome 
alongside short-term clinical outcomes of CRS patients undergoing endoscopic sinus surgery 
(ESS). Twelve patients undergoing ESS to treat their CRS were enrolled in this study and 
randomly distributed into two groups: an antibiotic treatment group and a placebo treatment 
group. The antibiotic treatment group received doxycycline for 28 days after surgery. Clinical 
information, including computed tomography scan, symptom questionnaires, and nasal 
endoscopy, were collected for each patient before and after ESS. Swab and tissue samples were 
collected and underwent DNA extraction, PCR amplification of the bacterial 16S rRNA gene, 
and amplicon sequencing analysis to longitudinally characterise each patient’s sinonasal 
microbiome. There were no differences in symptom scores or endoscopic/radiological scores 
between treatment groups before or after the surgery, and there was no significant difference 
in the microbiome between the treatment groups after surgery. Our preliminary study showed 
that post-operative antibiotics did not improve short-term clinical outcomes for CRS patients 
undergoing ESS, and there was no significant difference in the microbiome between 
treatments, either. However, our preliminary findings reflect only short-term effects, and many 
of our analyses were statistically underpowered due to the modest sample size. A larger study 
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1 Chapter One: Introduction 
1.1 Chronic rhinosinusitis  
Chronic rhinosinusitis (CRS) is an inflammatory disease affecting an estimated 5% to 
15% of populations in developed countries (Fokkens et al., 2012). This disease is characterised 
by inflammation of the paranasal sinuses and nasal cavity. Its symptoms include nasal 
congestion and discharge, facial pain/pressure, and a lack of smell. The presence of these 
symptoms for greater than 12 weeks is required to diagnose CRS; otherwise, it is classified as 
acute sinusitis (Barshak & Durand, 2017; Fokkens et al., 2012).  
The current guidelines for the clinical diagnosis and standard research requirements for 
CRS are set by the European Position Paper on Rhinosinusitis and Nasal Polyps 2012 (EPOS) 
and defined as the following (Fokkens et al., 2012): 
● Inflammation of the nose and paranasal sinuses with two or more symptoms 
which must include nasal discharge or nasal blockage/obstruction/congestion: 
o ± facial pain/pressure 
o ± reduction or loss of smell 
And either  
● Endoscopic signs: 
o nasal polyps 
o mucopurulent discharge primarily from the middle meatus  
o oedema/mucosal obstruction  
and/or 
● Computed tomography scan changes 
o mucosal changes within the ostiomeatal complex and/or sinuses.  
 
CRS is often differentiated into two distinct subtypes based on the presence of nasal 
polyps (Yang et al., 2015). CRS with nasal polyps (CRSwNP) is diagnosed by the presence of 
polyps in the nasal and paranasal sinuses when examined endoscopically, whereas a lack of 
polyps is diagnosed as CRS without nasal polyps (CRSsNP) (Figure 1.1). CRSwNP accounts 
for approximately 20% of CRS cases (Hayes et al., 2015). Current studies suggest that these 
two subtypes may be distinct diseases based on the different inflammatory responses of the 
subtypes (Yang et al., 2015); however, the pathogenesis of these subtypes remains complex 
with some overlapping features between these subtypes (Lam et al., 2015; Yang et al., 2015). 
CRSwNP is associated with T helper2 cells and eosinophilic inflammation (Foreman et al., 
2011; Maxfield et al., 2017; Yang et al., 2015), whereas CRSsNP is driven by T helper1 cells 
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and has been associated with less severe inflammation of the mucosa and lower eosinophils 
present compared to CRSwNP (Foreman et al., 2011; Hayes et al., 2015; Yang et al., 2015). 
 
 
1.2 CRS assessment methods 
1.2.1 22-item Sino-Nasal Outcome Test 
A 22-item Sino-Nasal Outcome Test (SNOT-22) is a commonly used test to assess the 
severity of CRS and can be used to determine the likelihood of a patient willing to undergo 
surgical treatment (DeConde et al., 2014). This test is scored using 22 symptoms of the disease 
on a scale of 0 to 5 (5 for the most severe symptoms) with a maximum score of 110 (DeConde 
et al., 2014). Alongside assessing the likelihood that a patient will undergo surgery, this test 
has also been used in research and clinical settings to determine the effectiveness of CRS 
treatments. A reduction in a patient’s SNOT-22 score indicates better clinical outcomes for the 
patient due to a reduction in the severity of their symptoms (DeConde et al., 2014).  
 
1.2.2 Lund-Mackay System 
The Lund-Mackay system (LMS) accesses the disease extent in patients with CRS 
(Lund & Mackay, 1993). LMS grades each sinus group (maxillary, anterior ethmoids, posterior 
ethmoids, sphenoid, frontal, ostiomeatal complex) using computed tomography (CT), on a 
scale of 0 to 2 (0: no abnormalities, 2: occluded) for the left and right sinus (Lund & Mackay, 
1993). This test's total score range is 0 to 24 and can be used to assess the disease's severity, 
both pre- and post-operatively (Lund & Mackay, 1993). This assessment method has been 
Figure 1.1: CT scan of sinonasal blockages in a healthy patient (A), CRS patient without nasal polyps (B), and 
CRS patient with nasal polyps (C) (Hoggard, Wagner Mackenzie, et al., 2017). 
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previously found to be correlated with the extent of the disease and offers an objective 
assessment of the disease severity (Hopkins et al., 2007). This method should be used alongside 
a SNOT-22 score to indicate disease severity and if surgical interventions are required 
(Hopkins et al., 2007). 
 
1.2.3 Modified Lund-Mackay Postoperative Endoscopy Score 
The Modified Lund-Mackay Postoperative Endoscopy Score (MLMES) is another 
commonly used method to assess the severity of CRS in post-operative sinus cavities. This 
method considers the sinuses' appearance when examined using an endoscope rather than using 
symptoms or CT scans, unlike the previous techniques (Snidvongs et al., 2013). MLMES 
scores all ten post-operative sinus cavities (left and right maxillary, ethmoid, sphenoid, frontal 
sinuses, and olfactory fossa) and gives an overall score ranging from 0-100 (the higher the 
number, the more severe the disease).  
Both LMS and MLMES are used when assessing disease severity in research and for 
endoscopic sinus surgery (ESS) referrals; however, unlike self-reported SNOT-22 scores, LMS 
and MLMES scores are more objective and reproducible across multiple patients (Snidvongs 
et al., 2013). These methods can give an overall view of the severity of CRS in a patient based 
on both clinical and symptom severity.  
 
1.3 Epidemiology  
CRS is a common disease estimated to currently affect 14-30 million American adults 
(Anderson et al., 2016; DeConde & Soler, 2016; Hamilos, 2011). The National Health 
Interview Survey carried out in the U.S. reported a 12.1% prevalence of diagnosed sinusitis in 
adults by a health care provider in 2012 (Blackwell et al., 2014). This survey included 234,921 
adults and found a higher prevalence of sinusitis in females and Caucasians (Blackwell et al., 
2014). This survey, however, did not differentiate between chronic or acute sinusitis. Another 
U.S. survey using self-reported symptoms estimated a prevalence of 13.5%, which was 
confirmed by another survey suggesting 16% of adults in the U.S. had this condition (Blackwell 
et al., 2002; Collins, 1997). The prevalence of CRS also appeared to be affected by age, with 
increasing CRS rates in older populations; patients aged 20-29 had a prevalence of 2.7%, while 
patients aged 50-59 had a prevalence of 6.6% (Fokkens et al., 2012). A nationwide survey in 
Korea found a prevalence of 1% for CRS diagnosis (Min et al., 1996), while a U.S. study in 
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2000 based on medical records found a prevalence of 1.96% (Shashy et al., 2004). These results 
demonstrate the potentially exaggerated prevalence reported in self-reported studies and the 
geographic variability of the disease. Prevalence based on medical records also has a bias with 
reported numbers due to patients not seeking medical help for the disease, resulting in an 
underestimation of its prevalence. Accurate estimates regarding CRS's prevalence are also 
limited since the current diagnostic criteria for CRS were only recently developed (DeConde 
& Soler, 2016; Hamilos, 2011). 
 
1.4 Pathogenesis of CRS 
CRS is thought to be a heterogeneous disease resulting from multiple host and 
environmental factors (Foreman et al., 2011). There currently is no evident causative agent 
behind this disease; however, bacteria are thought to play an important role (Anderson et al., 
2016; Jain et al., 2018). Historically, this disease was thought to have been due to infection, 
but recent advances in cultivation-independent techniques have suggested that the pathogenesis 
of CRS is comprised of several mechanisms, including anatomical abnormalities, genetic 
disorders, biofilms, pathogenic bacteria, and bacterial dysbiosis (Lam et al., 2015). 
 
1.4.1 Bacterial 
 Bacterial dysbiosis has been suggested as a mechanism behind CRS (Cho et al., 2020; 
Copeland et al., 2018; Hoggard, Biswas, et al., 2017). According to this hypothesis, deviations 
from the typical microbial community (i.e., microbial homeostasis) can lead to the development 
or maintenance of CRS (Anderson et al., 2016; Copeland et al., 2018; Hoggard, Biswas, et al., 
2017). A shift in community structure can be caused by a range of factors, including antibiotics 
that have been shown to affect microbial biodiversity (Feazel et al., 2012). It is thought that the 
abundances of keystone species change due to a range of different events such as a decrease in 
nasal epithelial integrity or antibiotics, allowing for the growth of rare pathogenic or 
opportunistic species (Copeland et al., 2018; Hoggard, Biswas, et al., 2017). The increased 
abundance of these pathogenic or opportunistic bacteria is presumed to contribute to the 
maintenance of the disease (Copeland et al., 2018; Hoggard, Biswas, et al., 2017). 
 Staphylococcus aureus has been suggested to have a role in CRS and is linked to poor 
surgical outcomes and prognosis (Anderson et al., 2016; Fokkens et al., 2012; Jain et al., 2017; 
Jervis-Bardy et al., 2009). S. aureus present in the submucosa has been found in high 
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abundance in CRS patients and is thought to impact the patient’s immune system by releasing 
interleukin-6 and supporting other pathogenic evasions (Hoggard, Wagner Mackenzie, et al., 
2017). The presence of S. aureus has also been suggested to reduce the presence of anti-
inflammatory interleukin-10, thereby increasing inflammatory responses (Sivasubramaniam & 
Douglas, 2018). S. aureus super-antigens create exotoxins which are thought to affect T helper2 
swelling, mast cell activity, and promote eosinophil release, leading to an increase in 
inflammation and tissue damage in the sinuses (Fokkens et al., 2012). These super-antigens are 
thought to be disease modifiers rather than the primary aetiology. S. aureus has also been 
associated with increased risk of CRS and increased chance of relapse after endoscopic sinus 
surgery (ESS) (Hoggard, Biswas, et al., 2017). It is thought that S. aureus enters the patient’s 
cells in the form of small colonies, allowing these bacteria to escape the host’s immune 
response and act as a reservoir for super-antigen release into the sinuses (Foreman et al., 2011; 
Kim et al., 2015). There is, however, contradictory evidence regarding the role of S. aureus in 
CRS. Some studies have found an increased abundance of S. aureus in CRS patients, while 
other studies found similar abundances between healthy and CRS patients (Anderson et al., 
2016; Feazel et al., 2012; Hoggard, Wagner Mackenzie, et al., 2017). These conflicting results 
make it difficult to draw any conclusions about the role of S. aureus in CRS and whether this 
bacterium is a modifier, causative agent, or just a local species present in the sinuses.  
Biofilms, both fungal and bacterial, have also been speculated to be a factor in CRS and 
have been suggested to play a role in maintaining inflammation in the sinuses (Fokkens et al., 
2012; Hayes et al., 2015; Wood & Douglas, 2010). A study by Dlugaszewska et al. (2016) 
found that 77% of CRS patients had evidence of biofilm presence while the EPOS reported 
biofilm presence rates of 30-100%  (Fokkens et al., 2012). The large variability of detected 
biofilms may be due to the different methodologies used for detection. Biofilms are 
hypothesised to worsen CRS by releasing free-floating bacteria from a reservoir formed in 
these biofilms, which protect bacteria from antibiotics and other host defences (Fokkens et al., 
2012; Kim et al., 2015). S. aureus has also been identified as a common biofilm-forming 
bacterium in CRS patients with a colonisation rate of 27% in CRSsNP patients and 60% of 
CRSwNP patients (Hayes et al., 2015; Wood & Douglas, 2010). The presence of biofilm-
forming S. aureus may explain why patients may still have inflammation even after antibiotic 
treatment, as medications would be unable to breach the biofilm and therefore not affect S. 
aureus (Wood & Douglas, 2010). It is still uncertain if biofilms are a factor in the development 
of CRS, but biofilms in other diseases have been shown to reduce the effect of antibiotics and 
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the patient’s immune response, leading to a worse prognosis (Fokkens et al., 2012; Hoggard, 
Wagner Mackenzie, et al., 2017).  
 
1.4.2 Non-bacterial  
 Non-bacterial factors that have been suggested as causative agents or to impact severity 
of CRS include aspirin sensitivity, allergy, asthma, immune deficiencies, genetic and 
anatomical abnormalities (Anderson et al., 2016; Copeland et al., 2018). The patient’s immune 
system is thought to contribute to the inflammatory characteristics of CRS (Stevens et al., 
2015). The anatomy of the sinuses can play a role in CRS incidences since it can influence the 
sinuses' clearance and increase the risk of developing inflammation. Narrow sinus drainage 
pathways have been suggested to predispose patients to CRS, while other anatomical 
abnormalities that have also been linked to CRS include septal deviation, atypical ethmoid 
cells, concha bullosa, etc. (Wood & Douglas, 2010). Several disorders and conditions 
predispose the patient to CRS, including cystic fibrosis, Kartagener’s syndrome, and primary 
ciliary dyskinesia (Fokkens et al., 2012; Lam et al., 2015). These factors may be associated 
with CRS due to the effect these conditions have on ciliary and mucus transport (Fokkens et 
al., 2012). However, most CRS cases do not have these underlying conditions, and the cause 
of the disease is currently unknown in these cases (Wood & Douglas, 2010).  
 Allergic rhinitis has been suggested to predispose individuals to CRS. However, some 
studies have suggested that allergic rhinitis is a superimposed problem that can contribute to 
CRS inflammation rather than predisposing (Lam et al., 2015). Allergic rhinitis can aid in 
obstructing the sinuses due to the inflammation of the nasal mucosa, which can hinder 
ventilation and retain mucus (Fokkens et al., 2012; Lam et al., 2015; Wood & Douglas, 2010). 
The role of allergies in CRS remains uncertain; however, the prevalence of CRS is noted to be 
higher in those with allergies than without (Fokkens et al., 2012).  
 
1.5 CRS management and treatment  
1.5.1 Medical management of CRS  
Patients who suffer from CRS initially manage their symptoms through maximal 
medical therapy, which typically consists of corticosteroids, antibiotics, and saline nasal 
irrigation. These treatments have varying effectiveness due to the heterogeneity of this disease. 
The treatment used may also vary depending on the institution and patient consent. The 
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treatment is generally the same for both subtypes of CRS (CRSwNP and CRSsNP), except that 
antibiotic treatment is not recommended for patients with CRSwNP (Hamilos, 2011). 
Glucocorticoids are used for the treatment of CRS due to their anti-inflammatory 
effects. This medication has been shown to significantly improve patient symptoms when 
compared to patients who were treated with a placebo (Fokkens et al., 2012; Guilemany et al., 
2010; Hamilos, 2011). Glucocorticoids reduce eosinophil activity and viability, which leads to 
a reduction in the chemotactic cytokines secreted by the nasal mucosa and polyp epithelial, 
reducing eosinophil function (Fokkens et al., 2012; Guilemany et al., 2010). The delivery of 
this treatment is dependent on a range of different factors, including surgical state, delivery 
technique and device, and fluid dynamics (Fokkens et al., 2012). ESS has been shown to 
improve topical glucocorticoids' delivery to the sinuses, allowing for more effective treatment 
(Fokkens et al., 2012).  
Nasal irrigation is an effective complementary treatment for CRS and has been 
recommended in recent CRS consensus documents (Hamilos, 2011). Irrigation reduces 
postnasal drainage, rinses away allergens and irritants, removes secretions, improves 
mucociliary clearance, and can be performed with various over-the-counter devices (Hamilos, 
2011). Nasal irrigation has been shown to reduce symptoms and improves the endoscopic 
appearance of the nasal cavity and sinuses (Guilemany et al., 2010).  
Antibiotics use for CRS treatment remains controversial due to a lack of evidence 
supporting the use of this medication for CRS (Guilemany et al., 2010). Some studies have 
found that short-term oral antibiotics improve symptoms, while other studies found no 
significant differences between control and treated patients (Guilemany et al., 2010). There is 
a concern about the development of antibiotic resistance and the other potential side effects of 
this medication, such as gastrointestinal upset, skin rash, allergic reaction, and elevation of 
liver enzymes (Fokkens et al., 2012). Long-term antibiotics, such as macrolides, have also been 
a suggested treatment due to the anti-inflammatory and antibacterial effects. These antibiotics, 
however, have also been proposed to affect the host immune response, which could lead to 
antibiotic resistance and, as such, is only recommended for patients who do not respond to 
other medical interventions (Fokkens et al., 2012; Guilemany et al., 2010; Hamilos, 2011). 
There is no FDA-approved antibiotic for the treatment of CRS currently due to the uncertainty 




1.5.2 Surgical management of CRS 
Patients who do not respond to medical treatments may be offered the opportunity to 
undergo surgical intervention to help reduce their symptoms (Murthy & Banerjee, 2013). A 
common surgery to undergo as a treatment for difficult to treat CRS is ESS (Sethi & 
Chakravarti, 2016; Wood & Douglas, 2010). During an ESS, tissue, nasal polyps, and bone are 
removed from the sinus ostia to allow for more ventilation and greater mucociliary clearance 
(Fokkens et al., 2012). Other obstructions and inflamed tissue are also removed during this 
process (Fokkens et al., 2012; Hoggard, Wagner Mackenzie, et al., 2017; Jervis-Bardy et al., 
2009). The purpose of this surgery is to open up the sinuses to improve the drainage and airflow 
through the nose, decrease the severity of the disease, and improve the delivery of medication 
into the sinuses. ESS, in general, has a low complication rate of 0.69-2%; however, 
complications include infections, toxic shock syndrome, ecchymosis, and epistaxis (Shafik & 
Youssef, 2013). 
ESS has been shown to reduce the severity of symptoms for individuals who suffer 
from CRS, with one study showing an average improvement rate of 91% (Terris & Davidson, 
1994). Of the 91% improvement rate, 63% reported very good results, while another 28% 
reported good results (Terris & Davidson, 1994). Another study saw a 97.5% improvement, 
with 85% of patients reporting significant symptom improvement (Senior et al., 1998). This 
study also found that after an average of 7.8 years (6.3 to 11 years), there was a decline in 
antibiotic usage by 82% after the ESS (Senior et al., 1998). A study by Smith et al. (2013) 
found an improvement in quality of life for patients who underwent ESS compared to patients 
who continued with medical therapy. The success of the surgery for patients with CRSwNP is 
dependent on what caused the formation of these polyps – whether formed by idiopathic CRS 
pathways or underlying conditions such as cystic fibrosis (Fokkens et al., 2012). One study 
found 12% of patients who undergo this surgery are likely to have revision surgery, while 
another reported revision surgery as high as 20% (Fokkens et al., 2012; Terris & Davidson, 
1994). Revision surgeries have increased risk of complications and an increased risk of revision 
surgery, with success rates ranging from 50-70% in revision surgeries (Fokkens et al., 2012).  
 Certain conditions such as asthma, cystic fibrosis, and allergies have been linked to 
worse surgical outcomes and higher chances of undergoing revision surgery (Fokkens et al., 
2012; Hopkins et al., 2007; Murthy & Banerjee, 2013; Senior et al., 1998). Patients who also 
have a high olfactory disruption have also been shown to have worse surgical outcomes 
(Murthy & Banerjee, 2013). The presence of S. aureus has also been linked to unfavourable 
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post-operative outcomes (Fokkens et al., 2012). A decrease in bacterial diversity has also been 
linked to unfavourable post-operative outcomes, however, the cause behind this phenomenon 
remains uncertain (Hoggard, Wagner Mackenzie, et al., 2017).  
For some patients, additional procedures are recommended while undergoing ESS. 
These adjunct surgeries work together with the ESS to give better outcomes for the patient than 
what would have been achieved with just ESS. These surgeries are often used to reconstruct 
the sinuses. Common examples of adjunct surgeries for CRS include septoplasty (septo) and 
turbinoplasty (ITs). Septoplasty is a surgical procedure that can be done alongside ESS to 
correct nasal septal deformities (Hwang et al., 1999; Orabona et al., 2018). Nasal septal 
deformities have previously been implicated with diseases such as sinusitis and can cause a 
basal obstruction in the patient (Orabona et al., 2018). For this procedure, the septal is 
straightened by removing the inner lining and removing bent cartilage (Hwang et al., 1999). 
Turbinoplasty is a procedure used to reduce the inferior turbinate bone, which can become 
swollen in CRS patients (Friedman et al., 1999). The techniques used for this process can differ 
depending on the clinician, but the overall procedure involves removing lining tissue of the 
turbinate to allow access to the bone, which is then reduced in size (Friedman et al., 1999). 
These surgeries are used to reduce nasal obstruction further to allow for better clinical 
outcomes for the patient (Friedman et al., 1999; Orabona et al., 2018). 
 
1.6 Microbiome of CRS 
The human microbiome has been shown to significantly impact an individual's health 
and diseases (Cho & Blaser, 2012). Previous research into the gut microbiota has demonstrated 
that the microbiome plays a role in the immune system, protection against pathogens, 
susceptibility to inflammation, diseases such as obesity, and more (Cho & Blaser, 2012; 
Ramakrishnan et al., 2015). Research investigating CRS has suggested that this disease might 
also be influenced or maintained by the microbial community present in the paranasal sinuses, 
with several studies finding links between the sinus microbiome and CRS (Ramakrishnan et 
al., 2015).  
Until surprisingly recently, the sinuses were thought to be sterile in healthy patients, 
whereas the presence of bacteria indicated a diseased state (Sivasubramaniam & Douglas, 
2018). This theory was disproved as new molecular techniques arose, identifying diverse 
microbial communities present in both diseased and healthy sinuses. Studies have found that 
the microbial communities for CRS and healthy patients are similar and composed primarily 
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of Firmicutes, Actinobacteria, Proteobacteria, and Bacteroidetes (Copeland et al., 2018; 
Hoggard, Biswas, et al., 2017; Jain et al., 2017; Sivasubramaniam & Douglas, 2018). Patients 
with CRS were found to have a higher relative abundance of Proteobacteria (Copeland et al., 
2018). Corynebacterium has been found at a higher reactive abundance for the healthy patients, 
while Escherichia was found in a higher relative abundance for CRS patients (Copeland et al., 
2018; Hoggard, Biswas, et al., 2017). Healthy patients tend to have a lower abundance of 
pathogenic organisms present than patients with CRS (Sivasubramaniam & Douglas, 2018). A 
study by Feazel et al. (2012) found a significant difference at a community level between 
patients with CRS and healthy patients; however, this difference may have been due to 
treatment of CRS, i.e., antibiotics, rather than the disease. There is a high amount of inter-
individual variation for healthy and diseased states, but this variation is expected given the 
different host and environmental factors influencing individuals' microbiome (Ursell et al., 
2012).  
Feazel et al. (2012) found that S. aureus had a similar prevalence between healthy 
patients and CRS patients, but found a higher relative abundance of S. aureus in patients with 
CRS than healthy patients. A review by Wang et al. (2020) suggested that the role S. aureus 
has in the microbiome of CRS patients is not as significant as other studies have suggested 
previously, due to the relative abundance of  S. aureus in some studies being found in similar 
or at higher abundances in healthy patients. The overall role S. aureus has in the microbiome 
of CRS patients currently remains unclear. Other specific bacteria such as Pseudomonas and 
some species of Corynebacterium have been associated with worse symptoms or quality-of-
life in patients with CRS (Wang et al., 2020). Aurora et al. (2013) also found Corynebacterium 
accolens and Curtobacterium at higher relative abundances in CRS patients than the healthy 
control patients. This study also found that Alicycliphilus and Cloacibacterium had a lower 
relative abundance in CRS patients (Aurora et al., 2013).  
Several studies have found evidence of microbial dysbiosis occurring in patients with 
CRS, which has been suggested to play a role in this disease's mechanism (Cho et al., 2020; 
Copeland et al., 2018; Ramakrishnan et al., 2015). Copeland et al. (2018) suggest that external 
influences on the sinonasal microbiome result in a shift from a stable to unstable microbiome 
(dysbiosis), leading to a prevalence of Staphylococcus, Propionibacterium, and 
Corynebacterium in CRS patients along with changes in the alpha diversity. A study by 
Ramakrishnan et al. (2015) found that while a large proportion of bacteria species identified in 
their study were present in both healthy and diseased patients, some of the bacteria present also 
correlated with a population variable and the patient's diseased state (Ramakrishnan et al., 
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2015). This study suggested that Bacteroides and Fusobacteria may act as opportunistic 
pathogens in some CRS patients, while phyla such as Actinobacteria and genus 
Corynebacterium may be predictive of the surgical outcomes in CRS patients (Ramakrishnan 
et al., 2015). High interindividual variation present within healthy and CRS patients has made 
it difficult to completely understand what a stable or unstable microbial community may look 
like, which makes it challenging to determine if dysbiosis plays a role, and what microbial 
species are involved with dysbiosis (Cho et al., 2020; Ramakrishnan et al., 2015). In general, 
studies have noted an increased abundance of opportunistic pathogens in CRS patients, 
suggesting that dysbiosis may play a vital role in the maintenance or development of CRS (Cho 
et al., 2020).  
The microbiome of CRS has been investigated using molecular techniques in multiple 
studies; however, the role of post-operative antibiotics after ESS has not been thoroughly 
investigated using molecular techniques. Previous studies have investigated the role of post-
operative antibiotic for CRS patients undergoing ESS using symptom questionnaires and 
endoscopic images of the sinuses, but there is a lack of understanding of changes in the 
microbial communities during this process (Albu & Lucaciu, 2010; Hauser et al., 2016; Jiang 
et al., 2008; Lehmann et al., 2020; Liang et al., 2011; Wu et al., 2019). Investigating the 
microbiome of patients with CRS who received post-operative antibiotics compared to those 
who received placebo may elucidate the role antibiotics play in the recovery process for ESS, 
and the role the sinonasal microbiome plays in recovery from ESS. Alongside this information, 
investigations into post-operative antibiotics after ESS may also give insight into the general 
role of the sinonasal microbiome in CRS and identify the role microbial dysbiosis plays in this 
disease. Overall, more research is needed using molecular techniques to understand the role 
microbial communities play in CRS, including post-operative antibiotic usage after ESS.  
 
1.7 Current research into antibiotic use associated with ESS 
It is currently standard practice for patients to receive 7 to 14 days of post-operative 
antibiotics after ESS to reduce the risk of post-operative infection, which could affect healing 
time and improve surgical outcomes. However, there is little research to support the 
prophylactic use of post-operative antibiotics, and questions of the efficiency of post-operative 
antibiotics have arisen in recent research (Jiang et al., 2008; Lehmann et al., 2020; Lux et al., 
2020; Saleh et al., 2012). Current research on antibiotics has identified an increasing trend of 
antibiotic resistance present in bacteria due to many factors, including the use and over-
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prescription of antibiotics in the medical field (Lehmann et al., 2020; MacGowan & 
Macnaughton, 2017). A study by Harbarth et al. (2000) investigated the prolonged use of 
prophylactic antibiotics after cardiovascular surgery and found that post-surgical antibiotic 
usage after 48 hours increased the risk of acquired antibiotic resistance and did not reduce rates 
of surgical site infection. The World Health Organisation has described increased incidences 
of antibiotic resistance as a major public health concern, potentially resulting in a post-
antibiotic era where minor injuries and infections can kill (World Health Organization, 2014). 
An estimated 25,000 people in the European Union already die each year due to antibiotic-
resistant infections (Baym et al., 2016). Another risk of antibiotics is the potential adverse side 
effects, including low white blood cells and blood platelet counts, anaphylaxis, gastrointestinal 
pain, nausea, and infections (Cunha, 2001).  
A study by Jiang et al. (2008) investigated prophylactic antibiotic use 
(amoxicillin/clavulanate) after ESS using LMS, swab cultures (anaerobic and aerobic cultures), 
antibiotic sensitivity testing, and symptom severity. The study found that symptoms scores for 
both the control group and those treated with antibiotics significantly decreased over time and 
that there was no significant difference between the two groups regarding endoscopic scores 
and culture results (Jiang et al., 2008). The bacterial growth in culture samples collected from 
antibiotic-treated patients increased after surgery, and the bacteria identified from the cultures 
varied significantly before and after the ESS (Jiang et al., 2008). This study concluded that 
their results demonstrated that antibiotics did not cause an improved outcome for patients 
compared to those treated without antibiotics. However, it should be noted that this study did 
not investigate the long-term impact of antibiotics usage and that investigators were not blinded 
for this study, which may have led to a bias in the results.  
Liang et al. (2011) investigated the differences in ESS outcomes for groups treated 
using amoxicillin, Chinese herbal medicine, and a placebo. This study compared pre- and post-
operative bacterial culture rates (anaerobic and aerobic) alongside CT scores, endoscopic 
scores, and a rhinosinusitis outcome measure. Bacterial culture rates increased significantly for 
patients treated with amoxicillin, whereas patients treated with Chinese herbal medicine or the 
placebo only had a slight increase in bacterial culture rates. S. aureus was the most common 
bacterium present in all three groups after the ESS (Liang et al., 2011). There was no significant 
difference between the three groups for endoscopic scores, CT scores, and rhinosinusitis 
outcomes (Liang et al., 2011). This study concluded that there was no significant benefit to 
using antibiotics or Chinese herbal medicine for post-operative ESS care in CRS patients.  
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Unlike the other studies, Albu and Lucaciu (2010) found that post-operative antibiotics 
may have improved ESS outcome regarding patient symptoms and moderately accelerated the 
healing. This study investigated bacterial culture rates, symptom scores, and endoscopic scores 
under double-blind, randomised conditions (Albu & Lucaciu, 2010). Both groups show 
significant improvements regarding self-reported symptoms scores, but individuals treated 
with antibiotics had a larger improvement for symptoms scores of nasal obstruction and 
discharge (Albu & Lucaciu, 2010). The endoscopic scores from days 5 to 12 were significantly 
different between the two groups, with patients treated with antibiotics recovering quicker 
(Albu & Lucaciu, 2010). This study did not discuss the bacteria cultures in detail and primarily 
focused on the patients' endoscopic and physical symptoms (Albu & Lucaciu, 2010; Rudmik 
et al., 2011). The authors attempted to justify using post-operative antibiotics due to bacterial 
adhesion to the healing wound that cannot be avoided, and the constant risk of infection present 
to all patients (Albu & Lucaciu, 2010).  
A study by Wu et al. (2019) compared the symptoms, endoscopic score, and swab 
cultures between patients using erythromycin and patients using intranasal steroids after ESS. 
When comparing steroid treatment to erythromycin treatment following ESS, the erythromycin 
treatment improved the endoscopic score in patients and symptoms such as smell (Wu et al., 
2019). The bacterial cultures for those treated with erythromycin and steroids had similar 
results. This study found that both treatments were effective and improved surgical outcomes; 
however, no conclusion about which treatment was better for post-operative care in CRS could 
be made as both treatments were effective (Wu et al., 2019). 
A study by Lehmann et al. (2020) also investigated post-operative antibiotics after ESS; 
unlike the previous studies, this was a noninferiority clinical trial. A noninferiority clinical trial 
determines if a new treatment is noninferior (not worse) to the standard treatment that is 
currently being used. In the study by Lehmann et al. (2020), the new treatment was a placebo 
(n = 37) whereas the standard treatment was post-operative antibiotics (n = 40).  Each patient 
underwent a Lund-Kennedy endoscopic score and SNOT-22 test to determine the surgery's 
effect on the patient's quality of life and clinical outcomes (Lehmann et al., 2020). Cultures 
were also collected from the sinuses once the ESS was completed; however, these were not 
discussed in detail (Lehmann et al., 2020). The study was performed under double-blind and 
randomised conditions. This study found that the placebo treatment group was non-inferior 
(i.e., not worse) to the antibiotic treatment group when only considering the patients' sinonasal-
specific quality of life (Lehmann et al., 2020). This study also found no significant difference 
in post-operative infection rates or endoscopic scores, but it noted a significantly higher rate of 
14 
 
diarrhoea in the antibiotic treatment group (Lehmann et al., 2020). Lehmann et al. (2020) did 
note that it was statistically underpowered due to the modest sample size and could not make 
any conclusive statements; however, this study did suggest that post-operative antibiotics may 
be unnecessary.  
The difference in these studies' outcomes may be due to variation in treatment such as 
steroids, nasal packaging, how extensive the surgery may have been, and time points used in 
their studies. A comparison of the Albu and Lucaciu (2010) and Jiang et al. (2008) suggests 
that post-operative antibiotics are an option for CRS patients undergoing ESS (Rudmik et al., 
2011). Still, professional judgement is needed from the clinician for each patient to determine 
the most appropriate treatment at the time, since the option of post-operative antibiotics should 
not be applied to all patients (Rudmik et al., 2011). Other studies and reviews such as Patel et 
al. (2018) and Saleh et al. (2012) suggest that the use of antibiotics should be withheld unless 
signs of infection are present.  
A limitation of the earlier studies is that they focused primarily on symptom and 
endoscopic results and did not adequately address the sinonasal microbiome (Albu & Lucaciu, 
2010; Jiang et al., 2008; Lehmann et al., 2020; Liang et al., 2011). When bacteria were 
investigated, culture-based methods were used; however, culture-based methods are not as 
effective as DNA-based molecular genetic methods (Albu & Lucaciu, 2010; Jiang et al., 2008; 
Lehmann et al., 2020; Liang et al., 2011). Previous research has indicated that 60 to 99% of 
microorganisms are uncultivable (Anderson et al., 2016). One study compared the results of 
clinical cultures to a molecular-based technique and found that the molecular-based approach 
detected a greater number of microorganisms (Feazel et al., 2012). Samples using molecular-
based techniques could detect organisms both found and missed when using culture-based 
techniques (Feazel et al., 2012). While culture-based methods may give some indication of 
what bacteria are present in the nasal cavity of patients, molecular-based methods have been 
shown to be more sensitive than culture-based methods, allowing for a complete understanding 
of the effects of antibiotics and the role the nasal microbiome may play in the recovery after 
ESS (Anderson et al., 2016; Feazel et al., 2012; Zapka et al., 2017).  
A study by Hauser et al. (2016) investigated the short-term effects of post-operative 
antibiotics on the sinonasal microbiome. This study used molecular-based techniques, 16S 
rRNA gene PCR amplicon sequencing and quantitative PCR, to examine the changes in the 
microbiome of 13 patients at three time-points: pre-operative, 2 weeks post-operative, and 6 
weeks post-operative (Hauser et al., 2016). All patients in this study received a two-week 
course of post-operative antibiotics (Hauser et al., 2016). Hauser et al. (2016) found that the 
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overall bacteria burden (determined using quantitative PCR) was higher at the two-week 
timepoint compared to pre-operative and six weeks post-operative timepoints (Hauser et al., 
2016). This study also found that the bacterial composition was similar for the pre-operative 
and six-week post-operative samples, indicating that the microbiome was repopulated or 
returned to baseline after surgery (Hauser et al., 2016).  Unfortunately, Hauser et al. (2016) did 
not include a placebo control, and its findings therefore cannot inform or rationalise the use or 
disuse of post-operative antibiotics. 
In summary, more research is needed to rationalise post-operative antibiotic use or 
disuse after ESS. Although several studies have shown that antibiotics have no impact on 
symptoms or endoscopic outcomes of the surgery, other studies have demonstrated better 
surgical outcomes for patients treated with antibiotics (Albu & Lucaciu, 2010; Jiang et al., 
2008; Lehmann et al., 2020; Liang et al., 2011). Alongside these contradictions, there has been 
no placebo-controlled clinical trial for post-operative antibiotic in CRS patients using 
molecular techniques. This lack of a comprehensive understanding of the bacteria present in a 
patient's sinonasal microbiome makes it challenging to understand the role of bacterial 
dysbiosis that could occur due to antibiotics and its role in patient recovery. A greater 
understanding of the sinonasal microbiome could also enable associations between recovery 
and certain bacteria and give insight into the role of bacteria in this disease and its recovery. 
Overall, a cultivation-independent, placebo-controlled, double-blinded study investigating the 
microbial ecology in patients undergoing ESS is needed to further understand both the 
usefulness of antibiotics in this surgery and the potential role in the recovery of the patient.  
 
1.8 Sample collection location 
Mucus samples collected using swabs of the sinus mucosa are frequently utilised when 
investigating CRS and make up the majority of studies in this field (Kim et al., 2015). Other 
sampling methods, such as tissue samples collected during surgery, have also been used in the 
literature but much less frequently (Kim et al., 2015; Roediger et al., 2010). Sampling sites and 
techniques can vary significantly between studies, which may contribute to the lack of 
consensus on the role of bacteria in CRS (Kim et al., 2015; Roediger et al., 2010). The middle 
meatus is the most frequently used site when collecting swab samples from patients since this 
site is easily accessible, has high agreement (82% similarity) to microbial cultures collected 
from maxillary sinus aspirates, and because this location has drainage from three major sinuses 
(maxillary, anterior ethmoid, and frontal) (Cho et al., 2020; Dubin et al., 2005). A study by 
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Kim et al. (2015) investigated the bacterial composition of swab samples compared to tissue 
samples from the middle meatus using the 16S rRNA gene. This study found that the bacterial 
communities identified in the swab samples were also identified in the tissue samples, but not 
all bacteria present in the tissue samples were present in the swab samples (Kim et al., 2015). 
Statistical analysis comparing the swabs to tissue samples found a significant difference 
between the bacterial communities; however, further research is needed to validate these results 
(Kim et al., 2015).  Kim et al. (2015) suggest that this difference may be caused by the protected 
environment found in tissue along with the impact of the patients’ distinct immune responses 
to each environment. These factors may have led to distinct bacterial communities (Kim et al., 
2015). In contrast to Kim et al. (2015), a study by Bassiouni et al. (2015) found that there was 
no significant difference between microbial composition in swab and tissue samples collected 
from the sinuses. Bassiouni et al. (2015) found that tissue samples had a higher richness; 
however, this relationship was not significant. Overall, Bassiouni et al. (2015) found that swab 
and tissue samples had similar microbiomes. These results show that further studies are needed 
to determine whether swab samples are representative of the ‘true’ sinonasal microbiome as 
suggested by Bassiouni et al. (2015), or if swab samples may not identify all the bacteria present 
in this diseased environment as suggested by Kim et al. (2015).  
 
1.9 Research aims 
Due to the lack of research investigating the sinonasal microbiome in CRS patients 
undergoing ESS, the effects of post-operative antibiotics on the sinonasal microbiome are 
largely unknown. This research aims to longitudinally characterise the sinonasal microbial 
ecology of CRS patients undergoing ESS using molecular techniques and to investigate the 
differences in the sinonasal microbiome between post-operative antibiotic and placebo 
treatments. Previous research indicates that there may be differences between tissue and swab 
samples due to the formation of biofilms and bacterial communities in the underlying tissue, 





2 Chapter Two: Methods 
2.1 Clinical samples and data collection 
2.1.1 Patient recruitment  
Twelve patients undergoing ESS were recruited for this study from November 2019 to 
November 2020. Patient recruitment and sample collection were suspended from April to June 
2020 due to the COVID-19 pandemic. The participants were under the coordinating 
investigator's care before recruitment and identified from a surgical waiting list. Patients were 
contacted by the coordinating investigator about potential involvement in this study. If the 
patient was confirmed to be eligible for and interested in participating in the study, a patient 
information sheet and consent form were emailed to the patient. The patient received a follow-
up phone call from a research nurse to answer further questions and inquire if they wished to 
participate in the study. For patients who agreed to participate in this study, signed informed 
consent was collected on the surgery day. Patients were excluded from this study if they had 
one or more of the following exclusion criteria: 
• prior sinus surgery  
• underlying condition predisposing to CRS (e.g., cystic fibrosis, vasculitis) 
• unilateral sinusitis or a LMS (a pre-operative scan indicating the severity of CRS) 
score lower than 10 (i.e., radiological evidence of mild sinusitis) 
• antibiotic usage within 12 weeks prior to ESS 
• known allergy to study drugs 
• confirmed or possible pregnancy  
Patients were randomised in a double-blinded fashion and allocated to a treatment 
(placebo/antibiotic) group using Microsoft Excel’s RANDBETWEEN function by the hospital 
pharmacist. For 28 days after the ESS, six patients received doxycycline 100 mg by mouth 
twice daily, while the remaining six received a placebo by mouth twice daily. The following 
demographic information and clinical details about the patients were collected using hospital 
records prior to the ESS: age, sex, LMS score, disease subgroup (CRSwNP, presence of co-
morbid asthma), and any adjunctive surgical procedures (i.e., septoplasty, inferior 
turbinoplasties).  
This study received approval from the New Zealand Health and Disability Ethics 
Committee and the University of Waikato (reference number: 19/NTA/64/AM01, universal 
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trial number: U1111-1229-8735). Written and informed consent was obtained from all the 
participants prior to inclusion in this study. This study was registered online with the Australian 
and New Zealand Clinical Trial Registry (Reference number: ACTRN12619000505101p). 
 
2.1.2 Sample collection 
Swab samples of the middle meatus were collected from the nose's left and right side 
using sterile rayon-tipped swabs (Copan Diagnostics Inc., Murrieta, CA) at three time points: 
during the ESS, two weeks after ESS, and three months after ESS. Some samples for the final 
time point were collected earlier or later than expected (ranging from 6 weeks to 6 months) due 
to the COVID-19 pandemic. Tissue samples from the nasal mucosa were also collected during 
ESS. No prophylactic antibiotics or other topical medications were used prior to sample 
collection during ESS. Once all intra-operative samples had been collected, all patients 
received a single dose of intravenous cefazolin. The swab and tissue samples collected were 
immediately placed in separate 2-mL screw-cap tubes containing 450 µL of DNA/RNA Shield 
(Zymo Research, Irvine, CA, U.S). Samples were then transported to the Thermophile 
Research Unit at the University of Waikato, where the samples were stored at 4°C until 
processed within 4 days of collection. The remaining swab samples were collected in follow-
up appointments at an outpatient clinic. The nasal cavity was treated with a co-phenylcaine 
nasal spray which acted as an anaesthetic and decongestant. Swab samples from the middle 
meatus from the left and right side of the nose were then collected and placed in 450 μl of 
DNA/RNA Shield then transported to the Thermophile Research Unit at the University of 
Waikato. Prior to ESS and during later follow-up appointments, patients also completed a 22-
item Sinonasal outcome tool (SNOT-22 score). The endoscopic appearance of the sinus mucosa 
was graded at the 3-month follow-up appointment using MLMES.  
 
2.1.3 Surgical treatment and post-operative care 
All patients underwent the same routine clinical and surgical care during and after the 
surgery except for the randomised doxycycline or placebo medication. Each patient was also 
prescribed prednisone (20 mg) for 10 days post-operatively with frequent use of saline nasal 
spray and saline lavage in the initial post-operative period. At post-operative follow-up 
appointments, patients were examined with a rigid nasal endoscope, and debridement of clot 
and crusting was performed. After the two-week follow-up appointment, patients were 
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encouraged to continue with twice-daily saline lavage and topical steroids. All participants 
were provided with contact details of the research team to report any side effects that they 
believe may have been attributed to the study medication, which was documented. Patients 
were asked to return any unused study medications so that compliance could be monitored. 
 
2.2 Molecular genetic analyses 
2.2.1 DNA extraction 
Total DNA was extracted from tissue and swab samples using the ZymoBIOMICS 
DNA Microprep Kit (catalogue no. D4301, Ngaio Diagnostics, Nelson) according to the 
manufacturer’s protocol for samples preserved in DNA/RNA Shield. Extraction blanks were 
also extracted alongside the tissue and swab samples. These extraction blanks were created 
during each extraction using only the reagents from the ZymoBIOMICS DNA Microprep Kit. 
The extracted DNA was quantified using a Qubit Fluorometer following the dsDNA HS 
protocol (Thermo Fisher Scientific, Auckland) and stored at -20°C until further analysed. 
 
2.2.2 DNA amplification of 16S rRNA gene 
A two-step polymerase chain reaction (PCR) was used to amplify the V4 hypervariable 
region of the 16S rRNA gene from the extracted DNA. The Earth Microbiome Project primers 
with adaptor sequence added (5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
[515FB] and 5’-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG [806RB]) as 
described in the Quick-16S NGS Library Prep Kit (catalogue no. D6400, Ngaio Diagnostics, 
Nelson) were used for the first PCR. For the first PCR step, the reactions (20 µL) consisted of 
0.4 µL of bovine serum albumin (BSA) (0.8 mg/mL), 2 µL of dNTPs (2mM), 2 µL of 10X 
PCR buffer, 2 µL MgCl2 (50 mM), 0.5 µL of each primer (10 mM), 0.08 µL of Platinum Taq 
DNA Polymerase (Thermo Fisher Scientific, Auckland), 2 µL of template DNA (5 ng/uL), and 
10.52 µL molecular-grade DNA-free ultra-pure water (Thermo Fisher Scientific, Auckland). 
Triplicate reactions were done and pooled for each sample using the following thermocycler 
conditions: an initial 3-minute denaturation step at 94°C followed by 35 cycles of 45 seconds 
at 94°C, 60 seconds at 50°C, and 90 seconds at 72°C, with a final extension step at 72°C for 
10 minutes. All reactions were run on an Applied Biosystems ProFlex PCR System (Thermo 
Fisher Scientific, Auckland). Positive (1 ng of E. Coli genomic DNA) and negative (ultra-pure 
water) controls were run with every PCR. 
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An agarose gel electrophoresis was used to confirm successful PCR amplification. For 
this step, 1 µL of SYBR Safe (Thermo Fisher Scientific, Auckland) was combined with 5 µL 
of the pooled PCR product and loaded into the wells of a 1% agarose gel. 10 µL of a 1 Kb Plus 
DNA Ladder (Thermo Fisher Scientific, Auckland) was also loaded. The gel was run for 30 
minutes at 70 V then visualised using an Alpha Innotech Imaging System (Alpha Innotech, 
California, USA). 
To remove mitochondrial DNA that was also amplified during the first PCR, the PCR 
products underwent gel extraction using an E.Z.N.A. Gel Extraction Kit (catalogue no. D2500-
01, Custom Science, Auckland) according to a manufacturer’s protocol with some 
modification. These modifications to the manufacturer's protocol include the following 
changes: extra 20% of binding buffer was combined with the gel band, the gel band was 
incubated for a longer time (additional 8 minutes), samples were centrifuged at a lower RCF 
(4,000 RCF) when the sample was initially transferred onto the column (later centrifuge steps 
were as specified in the protocol), the elution buffer was heated (60⁰C) before being added to 
the column, and the elution buffer was incubated on the column for longer (additional 3 
minutes).  
The extracted 16S rRNA gene PCR amplicons underwent barcode addition using the 
Quick-16S NGS Library Prep Kit according to its non-quantitative protocol for barcode 
addition. An agarose gel electrophoresis was used to confirm that barcode addition was 
successful.  
 
2.2.3 Next-generation sequencing 
Following the manufacturer's protocol, the barcoded PCR amplicons were processed 
and normalised using SequelPrep Normalization Plate Kit (Thermo Fisher Scientific, 
Auckland). Once library normalisation was completed, 3 µL of each sample was pooled into a 
sterile 1.5 µL Eppendorf tube to form an amplicon library. 150 µL of the library was combined 
with 10 µL of 50X ethylenediaminetetraacetic acid (EDTA), and the EDTA-treated amplicon 
library was sent at room temperature to GENEWIZ in Suzhou, China. At GENEWIZ, the 
amplicon library was sequenced using an Illumina MiSeq DNA sequencer in a 2 x 250 bp 




2.3 Data analysis 
2.3.1 Bioinformatic analysis  
The raw FASTQ files from the Illumina MiSeq were imported into R (v4.0.2). ASV 
inference and initial filtering were performed using the ‘DADA2’ package (v.1.16.0) (Callahan 
et al., 2016). The forward and reverse reads' quality profiles were visually examined, and it 
was determined that truncLen trimming was unnecessary. Reads were then filtered to allow no 
“N” nucleotides using the following filtering parameters: maxN=0, (DADA2 requires no Ns) 
truncQ=2, rm.phix=TRUE, maxEE=2 (maximum number of “expected errors” allowed in a 
read). The reads were then truncated and trimmed using the following parameters: 
filterAndTrim(fnFs, filtFs, fnRs, filtRs), truncLen=c(240,160), maxN=0, maxEE=c(2,2), 
truncQ=2. Parametric error rates for the reads were visualised and evaluated, which showed 
that the estimated error rate had a good fit for the observed error rate. Forward and reverse 
reads were merged and denoised, and the amplicon sequence variants were constructed. 
Chimeras were removed with the removeBimeraDenovo function using the method 
"consensus" (appendix, Table 6-1). Taxonomy was assigned with the native implementation of 
the naive Bayesian classifier and a DADA2-formatted reference database for the SILVA v138 
database (Quast et al., 2013). 
Analysis of the sequence data was conducted in RStudio (v4.0.2), while clinical data 
analysis was conducted in Microsoft Excel. The taxonomic data and ASV data created using 
DADA2 were merged in R into a phlyoseq object along with a metadata file created using 
Excel (composed of patient information). This phyloseq object was statistically analysed using 
a range of R packages including: phlyoseq (v1.32.0) (McMurdie & Holmes, 2013), ggplot2 
(v3.3.3) (Wickham, 2016), vegan (v2.5-6) (Oksanen et al., 2007), knitr (v1.31) (Xie, 2015), 
tidyverse (v1.3.0) (Wickham et al., 2019), decontam (v1.8.0) (Davis et al., 2018), 
pairwiseAdonis (v0.0.1) (Martinez Arbizu, 2020) and breakaway (v4.7.3) (Willis & Bunge, 
2015). Contaminated taxa were identified from extraction blanks and the PCR negative control 
using the decontam package. These contaminated taxa were then removed from the dataset. 
Samples were removed from the dataset if they had fewer than 25,000 reads, while the 
remaining samples were rarefied to 25,000 reads. Before rarefaction, the samples' microbial 
diversity was investigated using the breakaway package to estimate species richness for each 
sample. Species richness was analysed in Excel using Two-Sample Assuming Unequal 
Variances or Paired Two Sample for Means in the Excel Add-in ‘Analysis ToolPak’. Non-
metric multi-dimensional scaling (NMDS) plots based on Bray-Curtis dissimilarities were used 
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to examine the dissimilarity between samples. Bacterial community composition was 
investigated using relative abundance of the most abundant genus (abundance >1%). Adonis2 








3 Chapter Three: Results 
3.1 General descriptions of data  
3.1.1 Sequencing data 
The 94 samples included in this study were composed of (for each patient) two swab 
and two tissue samples collected on the day of the ESS (T1), two swab samples collected 13 
days after the surgery (except for patient 2, which was collected after 15 days) (T2), and two 
swab samples collected after an average of 105 days (41-188 days) (T3). The T3 samples were 
collected once the patient had recovered from the surgery (a minimum of six weeks after 
surgery). No T2 samples were collected for patient 6 due to the COVID-19 lockdown. The T3 
samples had initially been intended to be collected after three months when the patients would 
undergo a routine check-up after the surgery; however, due to the COVID-19 pandemic, some 
patient samples could not be collected at the three-month point. This led to large variations in 
the time between ESS and the T3 sampling. Alongside the 94 samples, 22 extraction blanks 
and one PCR negative control were also processed and analysed. These samples underwent 
16S rRNA gene PCR amplicon sequencing. The sequencing data then underwent de-noising 
and quality filtering using the DADA2 pipeline. This process yielded 11,340 amplicon 
sequence variants (ASVs) across the 94 samples, 22 extraction blanks, and one PCR negative 
control.  
 
3.1.2 Clinical and demographical data 
Clinical data such as demographical data, SNOT-22 scores (collected before the ESS, 
two weeks post-operatively, and three months post-operatively), radiological scores (pre-
operative disease severity assessment through CT scans [LMS]), and endoscopic scores 
(assessing healing after surgery [MLMES]) were collected for all 12 patients (Table 3-1). 
SNOT-22 scores are a self-reported questionnaire used to assess the patient's symptoms and 
understand their recovery after ESS. LMS and MLMES are both clinical tests used to evaluate 
the severity of CRS in patients; however, unlike a SNOT-22 score, these tests are based on 
clinical results rather than self-reporting. LMS is measured through CT scans, whereas 
MLMES is measured using endoscopic images. The average age of the twelve patients was 
44±12.1 (26-59), seven patients had CRSwNP, and five patients had asthma (Table 3-1). Eight 
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of these patients also underwent adjunct procedures (septoplasty [septo] and turbinoplasty 
[ITs])1. Three patients in this study were female, while the remaining nine patients were male.  
92% of the patients showed an improvement in their symptoms at their final check-up. 
Patient 4, however, showed worse outcomes with an increased SNOT-22 score (Figure 3.1 and 
Table 3-1). Patient 1 did not show a significant improvement and still had a high SNOT-22 
score after three months (Figure 3.1). Patients 1 and 4 both received antibiotics. The average 
pre-operative SNOT-22 score for patients who received the antibiotic treatment was 43, 
compared with 54 for patients who received the placebo control (Figure 3.2). The average 
SNOT-22 score at the three-month check-up was 24 for patients receiving antibiotics and 15 
for patients receiving the placebo (Figure 3.2). Overall, both treatment and control groups 
showed improved results based on the patient’s self-reported symptoms (Figure 3.1). There 
was no significant difference in the pre-operative (unpaired t-test, p-value = 0.29) and three-
month (p-value = 0.27) SNOT-22 scores between the treatment groups, and both groups 




1 Adjunct procedures are additional surgeries undertaken while undergoing ESS to help 
alleviate symptoms of CRS in patients who have nasal abnormalities (septoplasty straightens 

















1 57 male Septo CRSsNP Nil Antibiotic 64 12 44 10 0 
2 26 male Septo CRSwNP Asthma Placebo 81 14 20 21 45 
3 27 female ITs CRSsNP Asthma Antibiotic 50 57 5 10 2 
4 51 male Nil CRSwNP Nil Antibiotic 43 40 49 20 50 
5 59 male Nil CRSsNP Nil Antibiotic 19 7 13 16 46 
6 59 male Nil CRSwNP Nil Placebo 37 4 5 15 10 
7 56 male Nil CRSwNP Asthma Placebo 65 12 21 14 4 
8 45 male Septo CRSwNP Nil Placebo 62 43 14 14 5 
9 30 female Septo CRSsNP Nil Placebo 46 31 20 12 6 
10 34 male Septo CRSwNP Asthma Antibiotic 39 37 15 11 8 
11 37 male Septo / ITs CRSsNP Nil Placebo 33 47 9 14 0 
12 43 female ITs CRSwNP Asthma Antibiotic 44 32 20 14 2 
Table 3-1:Clinical and demographic data collected from patients across 3 months during this study. Patients in yellow did not significantly improve their symptoms after recovering from 
surgery according to their pre-op and 3-month SNOT-22 scores. Low SNOT-22 scores (total score range = 0-110), LMS scores (total score range = 0-24), and MLMES scores (total score range 









The average LMS score for patients treated with antibiotics was 13.5 and 15 for patients 
receiving the placebo (Figure 3.3). Three months after surgery, the average MLMES score for 
Figure 3.1: SNOT-22 scores for each patient over the course of 3 months. A high SNOT-22 score indicates worse 
CRS symptoms while a decrease in SNOT-22 over time indicates that the ESS has been successful.  

















SNOT pre-op SNOT 2w SNOT 3m
27 
 
patients receiving antibiotics was 18, compared with 12 for patients receiving the placebo 
medication (Figure 3.3). There was no statistical difference between the two treatment groups 
for their LMS scores (unpaired t-test, p-value =0.49). The placebo group appears to have better 
endoscopic results at the three-month check-up; however, this is not statistically robust 




Four patients reported side effects of the medication, with three of the four patients 
receiving antibiotics and reporting common side effects of doxycycline (Table 3-2) (Medsafe, 
2019). Patient 11, who received a placebo treatment, reported a sore throat on day seven and 
was then given Augmentin (amoxicillin and clavulanic acid) by their general practitioner. 
Patient 3 presented with vomiting and stopped taking the antibiotics after 11 days due to the 
severity of their symptom.  
  




Patient  Treatment Side effects 
1 Antibiotic nil 
2 Placebo nil 
3 Antibiotic vomiting - patient stopped study medication on day 11 
4 Antibiotic dizziness, tiredness, diarrhoea 
5 Antibiotic nil 
6 Placebo nil 
7 Placebo nil 
8 Placebo nil 
9 Placebo nil 
10 Antibiotic nil 
11 Placebo developed sore throat (day 7 post-op) - given Augmentin as treatment. 
12 Antibiotic facial rash - day 1 post-op 
Table 3-2: Side effects reported by patients throughout this study. 
 
3.2 Quality control and decontamination of the sequencing data 
Contamination was observed in the DNA extraction blanks when they underwent 16S 
rRNA gene PCR amplification alongside the extracted DNA from patients before sequencing. 
These blanks were created during each batch of DNA extraction, containing no samples but 
instead composed only of the reagents present in the ZymoBIOMICS DNA Microprep Kit. 
Contamination was also observed in the PCR negative control once sequenced. The PCR 
negative control was created using ultra-pure water instead of sample DNA. The blanks and 
PCR negative control underwent the same procedures as the DNA collected from the patients 
to allow the contaminating taxa present to be removed later during the data analysis process.  
There did not appear to be much overlap between ASVs present in the extraction blanks 
and PCR control when compared to the patient samples (Figure 3.4), indicating that the 
contaminants were relatively minor components of the data for patient samples. The most 
abundant ASVs present in the extraction blanks were affiliated with Pseudomonas, 





Figure 3.4: Heatmap of ASV present in extraction blanks and patient samples. Samples were sorted horizontally by sample type. ASV present in the white box are abundant 
in extraction blanks whereas ASV abundant outside of this box are patient samples. 
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To remove contaminant taxa from the patient samples, the ‘decontam’ package was 
used according to the prevalence-based method (Davis et al., 2018). This method uses the 
extraction blanks to calculate the prevalence of known contaminants in clinical samples while 
also considering that clinical samples will have competing template DNA (from the sinus 
microbiome), causing some contaminants to be absent in the clinical samples (Davis et al., 
2018). Using chi-square statistics (presence-absence table) or Fisher’s exact tests, the 
probability that a taxon is a contaminant or non-contaminant is calculated (Davis et al., 2018). 
‘decontam’ identified 889 taxa as contaminants at a 0.5 threshold (higher sensitivity compared 
with the default threshold of 0.1) (Davis et al., 2018). This threshold was selected since the 
extraction blanks had a high number of reads. The taxa identified as contaminants (all relatively 
rare taxa in patient samples) were then removed.  
Samples with fewer than 25,000 reads appear to be under-sampled based on diversity 
indices (data not shown) so were considered anomalous (Figure 3.5) and removed using the 
pruning function in the ‘phyloseq’ package. Following this step, 16 samples were removed 
from the dataset; six of these samples had no reads, while the remaining ten samples had low 
read counts (Table 3-3). Correspondingly, 36 ASVs were removed, leaving a total of 6,595 
ASVs across 78 samples, which were rarefied to 25,000 reads each, resulting in 5,888 ASVs 
present in the dataset. Further filtering of this dataset was performed to remove other 
contaminants such as mitochondria and chloroplasts, ASV that did not appear more than twice 
across all samples, and ASVs that were not assigned to Bacteria at the domain level (i.e., non-


































3.3 Comparing sample position  
3.3.1 Community richness 
The alpha diversity of swab and tissue samples collected from the left and right sinuses 
were compared using observed richness, breakaway estimates, and Shannon indices (appendix, 
Table 6-2). Patients 11 and 12 were excluded from this analysis since only two samples from 
patient 11, and three from patient 12 remained in the quality-filtered final data set (Table 3-3).  
According to all three indices, the average alpha diversity was similar for left and right 




3.3.2 Community structure 
A non-metric multi-dimensional scaling (NMDS) plot was used to visualise the 
similarities between samples collected from the left and right sinus (Figure 3.7). There was no 
apparent clustering observed, with left and right samples intermixing throughout the graph. 
Figure 3.6: Alpha diversity of samples sorted according to sample position using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 
estimates were made using unrarefied data. 
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Adonis2 analysis showed no significant difference between the left and right samples (R2 = 




3.4 Comparing tissue samples with swab samples 
3.4.1 Community richness 
The alpha diversity for tissue samples and swab samples was compared using observed 
richness, breakaway estimates, and Shannon indices. Patients 11 and 12 were excluded from 
this analysis since tissue samples from these patients were removed from the final data set due 
to low read counts (Table 3-3). For this analysis, T2 and T3 swab samples were excluded as 
there was no tissue counterpart for these samples.  
The observed richness and breakaway estimates showed that tissue samples, on 
average, had significantly higher diversity than the swab samples (paired t-test for breakaway 
estimates, p-value = 0.016). In contrast, the Shannon index showed that swab samples had a 
higher diversity on average (Figure 3.8).  
Figure 3.7: NMDS plot of samples from patient 1-10, labelled according to sample position. Ordination based on Bray-





3.4.2 Community structure 
NMDS plot was used to visualise the similarity between the tissue and swab samples 
(Figure 3.9). The NMDS plot showed that tissue samples, in general, tended to cluster more 
closely together than the swab samples. When examining tissue and swab samples for each 
individual, there was no clear trend between swab and tissue samples (data not shown). 
Adonis2 analysis showed significant differences between tissue and swab samples (p-value = 
0.009).  
 
Figure 3.8: Alpha diversity of samples sorted according to sample type using observed richness, breakaway estimates, 
and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway estimates 






3.4.3 Community composition 
Both tissue and swab samples were composed primarily of Corynebacterium, 
Dolosigranulum, and Staphylococcus (Figure 3.10). Moraxella had high relative abundance in 
patient 10 for both swab and tissue samples. Patients 1, 3, 5, and 9 all had similar community 
compositions for tissue and swab samples. In contrast, the community compositions for tissue 
and swab samples from patient 2 were dissimilar. There was a high relative abundance of 
Escherichia-Shigella in the tissue sample 002_1_TL, while the swab samples for patient 2 were 
composed primarily of Staphylococcus with some Corynebacterium. The tissue samples from 
patient 4 also differed from swabs since sample 004_1_TR had Lawsonella present while the 
swab samples did not. The remaining samples for patient 4 had similar microbial composition. 
Patients 6 and 7 had a greater diversity of genera present in their tissue samples compared to 
their swab samples. Tissue samples from patient 8 had Streptococcus present, whereas swab 
samples did not. Tissue samples from patient 8 also had a higher relative abundance of 
Staphylococcus than their swab counterparts. Samples from Patient 10 differed depending on 
sample type; tissue samples had a higher relative abundance of Moraxella and lower relative 
abundance of Staphylococcus than the swab samples for this patient. Overall, both swab and 
tissue samples were primarily composed of Staphylococcus, Corynebacterium, and 
Figure 3.9: NMDS plot of samples from patient 1-10, labelled according to sample type. Ordination based on Bray-Curtis 
dissimilarities across T1 samples. 2D stress = 0.14, max residual = 0.025. 
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Dolosigranulum, with some exceptions (patients 6, 7, and 10). The relative abundance of these 
genera differed for the sample type in patients 2, 4, 6, 7, 8, and 10. However, Patients 1, 3, 5, 









Figure 3.10: Relative abundance (>1%) of T1 samples for patients 1-10 separated into type of sample (tissue vs swab). 
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3.5 Exploring pre-treatment microbiome patterns against patient 
clinical data 
To further understand what factors could influence the patients’ sinonasal microbiome, 
clinical data was investigated to see if any patterns correlated with the sinonasal microbiome. 
Swab samples were examined to see if categorical clinical factors could influence the sinonasal 
microbiome. Tissue samples were analysed separately in patients with asthma or nasal polyps. 
This is because tissue samples may be influenced differently to swab samples due to the effects 
of the immune system and biofilms that may have been present in these tissue samples. 
 
3.5.1 Pre-treatment microbiome patterns associated with asthma 
The alpha diversity for patients with and without asthma was compared for both swab 
and tissue samples. Alpha diversity indices were compared using observed richness, breakaway 
estimates, and Shannon. The alpha diversity for swab samples showed that patients with asthma 
had, on average, a significantly higher diversity than patients without asthma (unpaired t-test 
for breakaway estimates, p-value = 0.026) (Figure 3.11).  
The alpha diversity for tissue samples according to observed richness was similar 
(Figure 3.12). The Shannon index indicated that patients without asthma had a higher diversity 
on average. The relationship for patients with/without asthma was not statistically significant 





Figure 3.11: Alpha diversity of swab samples for patients with/without asthma using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 
estimates were calculated using unrarefied data. 
Figure 3.12: Alpha diversity of tissue samples for patients with/without asthma using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 
estimates were calculated using unrarefied data. 
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The NMDS plots of patients with/without asthma for both tissue and swab samples 
showed patients with asthma clustering together while patients without asthma (nil) were 
spread throughout the graphs (Figure 3.13). This indicated that patients with asthma all had 
microbiomes that were relatively similar to each other. Some patients without asthma had 
similar microbiomes to asthma patients, but the majority were dissimilar to asthma patients. 
Adonis 2 analysis of asthma in swab samples also showed a significant difference between 
patients with/without asthma (R2 = 0.24, p-value = 0.005). The same analysis for tissue samples 
showed less significant differences between patients with/without asthma (R2 = 0.11, p-value 







Figure 3.13: NMDS plot of swab samples (A) and tissue samples (B) sorted according to asthma. Ordination based on 






The community composition for swab samples in patients differs depending on whether 
the patients had asthma or not (Figure 3.14). Staphylococcus dominated asthma patients except 
for two samples (007_1_SL and 010_1_SL); they were dominated by Moraxella and 
Corynebacterium. The sinonasal microbiomes of patients who did not have asthma were 
dominated by Dolosigranulum, with four exceptions. The exceptions were dominated by 
Corynebacterium or did not appear to have a dominant genus. Staphylococcus was present at a 
low relative abundance in every sample with three exceptions: two nil samples (001_1_SL and 
008_1_SL) and one asthma sample (010_1_SL).  
Tissue samples showed a similar trend to swab samples, with distinct microbiomes that 
depended on whether the patient had asthma or not (Figure 3.15). The microbial composition 
for tissue samples in patients with asthma was similar to the composition in swab samples. A 
majority of the samples were dominated by Staphylococcus. Tissue samples in patients without 
asthma, however, differed from the swab samples. Corynebacterium dominated the majority 








Figure 3.14: Relative abundance (>1%) of swab samples for patients with/without asthma. 
Figure 3.15: Relative abundance (>1%) of tissue samples for patients with/without asthma. 
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3.5.2 Pre-treatment microbiome patterns associated with nasal polyps 
The alpha diversities for swab samples comparing patients with or without nasal polyps 
did not appear to show a significant difference between the means of patients with or without 
nasal polyps (unpaired t-test for breakaway estimates, p-value = 0.63) (Figure 3.16). The alpha 
diversities for the tissue samples of patients with or without nasal polyps showed that, on 
average, patients with or without nasal polyps had a similar richness (Figure 3.17) (unpaired t-





Figure 3.16: Alpha diversity of swab samples for patients with/without nasal polyps using observed richness, 
breakaway estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data 





Ordination plotting (NMDS) of patients with or without nasal polyps did not show any 
distinct clustering in swab samples or tissue samples (Figure 3.18). This was further confirmed 
with Adonis2 analysis, which showed no significant difference between patients with/without 
nasal polyps in the swab samples (R2 = 0.074, p-value = 0.219) and tissue samples (R2 = 0.086, 
p-value = 0.129). 
 
  
Figure 3.17: Alpha diversity of tissue samples for patients with/without nasal polyps using observed 
richness, breakaway estimates, and Shannon indices. Observed richness and Shannon indices were calculated 







Figure 3.18: NMDS plot of swab samples (A) and tissue samples (B) sorted according to presence of nasal polyps. Ordination 






3.5.3 Pre-treatment microbiome patterns of patients undergoing adjunct 
surgeries 
Adjunctive surgeries were also investigated to see if these procedures would impact the 
microbiome. Patients undergoing these procedures may have a different sinonasal microbiome 
due to anatomical abnormalities treated with adjunct surgery. Only swab samples were used 
for this analysis, as biofilms were not thought to play a role in the need for these surgeries.  
On average, the alpha diversity for patients who underwent septoplasty was higher than 
patients who did not undergo adjunctive surgery (Figure 3.19). However, the relationship 
between septoplasty and nil was not statistically significant (Unpaired t-test for breakaway 
estimates, p-value =0.099). No alpha diversity statistical analysis could be calculated for ITs 
patients due to the lack of samples. Using NMDS, no apparent clustering was observed (Figure 
3.20). Pairwise Adonis testing showed no significant difference between the different 




Figure 3.19: Alpha diversity of T1 swab samples sorted according to adjunct procedures using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 












Procedure R2 p-value 
Septo vs ITs 0.145 0.546 
Septo vs nil 0.051 1.00 
ITs vs nil 0.134 1.00 
Table 3-4: Pairwise Adonis analysis comparing adjacent procedures undertaken by patients using T1 swab 
samples. 
Figure 3.20: NMDS plot of T1 swab samples sorted according to adjunct procedures undertaken along with ESS. Ordination 
based on Bray-Curtis dissimilarities (2D stress = 0.13, max residual = 0.000014). 
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3.6 Exploring patterns between treatment groups 
3.6.1 Community analysis of the treatment groups 
To determine if antibiotics affected the outcome of ESS or influenced the sinonasal 
microbiome, the bacterial community structure and composition were compared between 
patients who received antibiotics and patients who received placebo. For this analysis, the T1 
samples were excluded as the medication had not been administered. Patient 11 was excluded 
as they had received antibiotics midway through the study (Table 3-2) and due to the lack of 
T2 or T3 samples. Patient 12 was also excluded from this analysis due to a lack of T2 or T3 
samples.  
The different treatment groups were compared using alpha diversity indices: observed 
richness, breakaway estimates, and Shannon (Figure 3.21). On average, the placebo treatment 
had a higher diversity according to all three indices after ESS; however, this relationship was 
not significant (unpaired t-test from breakaway estimates, p-value = 0.25). Using an NMDS 
plot, there did not appear to be any distinct cluster between the treatment groups (Figure 3.22). 
Both the placebo and treatment groups were intermixed throughout this plot. Adonis2 analysis 
also showed no significant difference between these two groups (R2 = 0.026, p-value = 0.504).  
Figure 3.21: Alpha diversity of T2 and T3 swab samples sorted according to treatment undertaken using observed 
richness, breakaway estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied 






3.6.2 Comparing timepoints for each treatment group 
The different treatment groups were further analysed by comparing placebo and 
antibiotics samples at separate timepoints. (T1, T2, and T3). The alpha diversity for the T1 
samples indicated that the placebo samples had a higher diversity on average according to the 
observed and breakaway estimate indices (Figure 3.23). This relationship was not shown to be 
statistically significant (unpaired t-test for breakaway estimates, p-value =0.17).  
The alpha diversities for the T2 timepoint showed that patients who received the 
placebo, on average, had higher diversity (Figure 3.24). This relationship was especially 
noticeable in the Shannon index; however, this relationship was not statistically significant 
(unpaired t-test for breakaway estimates, p-value =0.82).  
According to the observed and breakaway estimate indices, patients who received 
antibiotics had lower diversity than patients who received the placebo at the T3 timepoint 
Figure 3.22: NMDS plot of T2 and T3 swab samples sorted according to treatment undertaken after ESS. Ordination 
based on Bray-Curtis dissimilarities (2D stress = 0.16, max residual = 0.0038). 
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(Figure 3.25). There was no statistical difference between the two treatments at the T3 
(unpaired t-test for breakaway estimates, p-value =0.16).  
 
Figure 3.23: Alpha diversity of T1 samples sorted according to the treatment group using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 






Figure 3.24: Alpha diversity of T2 samples sorted according to the treatment group using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 
estimates were calculated using unrarefied data. 
Figure 3.25: Alpha diversity of T3 samples sorted according to the treatment group using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 
estimates were calculated using unrarefied data. 
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An NMDS plot for the T1 samples did not show any distinct clustering between the 
different treatment groups; however, a general trend appeared of the antibiotic samples 
grouping to the left axis and the placebo samples to the right (Figure 3.26). Adonis2 analysis 
for the T1 timepoint showed a statistically significant difference between the treatment groups 
(R2 = 0.19, p-value =0.008). The NMDS plot for the T2 samples showed no distinct clustering 
between the treatment groups (Figure 3.27). Unlike the T1 samples, Adonis2 analysis of the 
T2 timepoint did not show a significant difference between the treatment groups (R2=0.042, p-
value =0.604). The T3 samples also did not show any distinct clustering in the NMDS plot 




Figure 3.26: NMDS plot of T1 samples sorted according to treatment group. Ordination based on Bray-Curtis 




Figure 3.27: NMDS plot of T2 samples sorted according to treatment group. Ordination based on Bray-Curtis dissimilarities (2D 
stress = 0.13, max residual = 0.00095). 
Figure 3.28: NMDS plot of T3 samples sorted according to treatment group. Ordination based on Bray-Curtis 
dissimilarities (2D stress = 0.071, max residual = 0.000014). 
56 
 
All three timepoints were primarily dominated by Staphylococcus, Corynebacterium, 
and Dolosigranulum (Figure 3.29, Figure 3.30, and Figure 3.31). The antibiotic T1 samples 
were dominated by Corynebacterium and Dolosigranulum (Figure 3.29). The placebo T1 
samples were dominated by a variety of genus, including Staphylococcus and Dolosigranulum. 
Corynebacterium was present in both T1 treatments; however, had a higher relative abundance 
in antibiotic samples. Staphylococcus was found at higher relative abundances and higher 
prevalence in the T1 placebo samples. The T2 samples for both treatments were dominated by 
Staphylococcus (Figure 3.30). Corynebacterium dominated the six T2 samples that were not 
dominated by Staphylococcus. A variety of genus dominated the T3 samples for both 
treatments. Staphylococcus dominated the majority of the T3 placebo samples (Figure 3.31). 






Figure 3.29: Relative abundance (>1%) of T1 samples, sorted according to treatment. 






Figure 3.31: Relative abundance (>1%) of T3 samples, sorted according to treatment. 
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3.6.3 Comparing timepoints across antibiotic treatment samples 
Antibiotic samples were compared across timepoints to determine the effect antibiotics 
had on the sinonasal microbiome over time. The observed richness and breakaway estimate 
indices show that the T1 antibiotic samples had the lowest diversity of the timepoints while the 
T3 had the highest average diversity (Figure 3.32). The Shannon index showed that the T1 
antibiotic treatment had a similar richness for the T2 and T3. A paired t-test using breakaway 
estimates showed no statistical significance between these timepoints (Table 3-5). The NMDS 
plot of the different timepoints for the antibiotic samples did not show any distinct clustering 
and all three timepoints intermixed throughout the graph (Figure 3.33). Pairwise Adonis 
showed that the three timepoints were not statistically significant (Table 3-6).  
 
Timepoint p-value 
T1 vs T2 0.150 
T1 vs T3 0.217 
T2 vs T3 0.520 
Table 3-5: Paired t-test p-values for patients who received the antibiotic treatment, sorted according to the timepoint. 
Calculated using the breakaway estimate index. 
Figure 3.32: Alpha diversity of antibiotic samples sorted according to the timepoint using observed richness, breakaway 
estimate, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 





Timepoint R2 p-value 
T1 vs T2 0.14 0.150 
T1 vs T3 0.10 0.573 
T2 vs T3 0.16 0.096 
Table 3-6: Pairwise Adonis analysis comparing timepoints for patients who received the antibiotic. 
 
3.6.4 Comparing timepoints across placebo samples 
The different timepoints were compared for the placebo samples to determine what 
effect this treatment had on the sinonasal microbiome overtime. The alpha diversity using 
observed richness, breakaway estimates, and Shannon indices showed that the T1 placebo 
samples had the lowest diversity (Figure 3.34). The Shannon index showed that the T2 samples 
had the highest diversity, whereas the observed and breakaway estimate indices showed that 
the T2 and T3 had similar richness. A paired t-test using breakaway estimates showed that T1 
placebo samples compared to T3 placebo samples were statistically significant while T1 
compared to T2 and T2 compared to T3 placebo samples were not significant (Table 3-7). The 
Figure 3.33: NMDS plot of antibiotic samples sorted according to the timepoint. Ordination based on Bray-Curtis dissimilarities (2D 
stress = 0.21, max residual = 0.0027). 
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NMDS plot for patients who received the placebo did not show any distinct clustering between 
the different timepoints (Figure 3.35). Pairwise Adonis analysis of this data also showed no 





T1 vs T2 0.637 
T1 vs T3 0.046 
T2 vs T3 0.530 
Table 3-7: Paired t-test p-values for patients who received the placebo treatment, sorted according to the timepoints. 
Calculated using the breakaway estimates index. 
Figure 3.34: Alpha diversity of placebo samples sorted according to the timepoint using observed richness, breakaway 
estimates, and Shannon indices. Observed richness and Shannon indices were calculated using rarefied data while breakaway 






Timepoint R2 p-value 
T1 vs T2 0.158 0.084 
T1 vs T3 0.086 0.477 
T2 vs T3 0.073 0.849 
Table 3-8: Pairwise Adonis analysis comparing timepoints for patients who received the placebo medication. 
  
Figure 3.35: NMDS plot of placebo samples sorted according to the timepoint. Ordination based on Bray-Curtis dissimilarities 
(2D stress = 0.12, max residual = 0.0010). 
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4 Chapter Four: Discussion 
The composition of the sinonasal microbiome in CRS patients has received growing 
interest in recent years with the development of cultivation-independent techniques. The 
majority of the research in this area has been dedicated to comparing CRS patients' sinonasal 
microbiome to healthy patients. Few studies have investigated the sinonasal microbiome of 
patients undergoing ESS and the effect post-operative prophylactic antibiotics have on the 
microbial composition (Hauser et al., 2016). To our knowledge, this study was the first 
placebo-controlled double-blinded clinical trial investigating the relationship between the 
clinical outcomes of ESS and the post-operative treatment used with the sinonasal microbiome. 
Our study also investigated whether the microbial composition of swab samples usefully 
represents the microbial community in tissue samples.  
 
4.1 Tissue and swab samples have similar but distinct 
microbiomes 
Swab samples of the nasal mucosa are commonly used to study CRS patients' sinonasal 
microbiome; however, this sampling method's reliability has been questioned (Bassiouni et al., 
2015; Kim et al., 2015). Our study provided evidence that swab and tissue samples have distinct 
microbiomes. According to breakaway estimates and observed richness, tissue samples had 
higher richness than their swab counterparts (Figure 3.8). The Shannon indices, in contrast, 
indicated that swab samples had a higher richness. This difference could be explained by the 
fact that the Shannon index also accounts for evenness (Morris et al., 2014), indicating that 
swab samples have more evenly structured communities. The diversity patterns in our results 
contradicts the findings from Kim et al. (2015), which found no significant difference between 
swab and tissue diversity indices. Similar to our study, Bassiouni et al. (2015) found that tissue 
samples had higher richness than swab samples; however, this relationship was not significant 
in their study. Our results also showed that the beta diversity of swab and tissue samples was 
statistically different. The NMDS plot and Adonis2 analysis indicated that tissue samples were 
dissimilar to swab samples (p-value = 0.009). The difference in richness and dissimilarity 
between tissue and swab samples could be due to biofilms and mucosa tissue acting as barriers, 
preventing the swabs from collecting a representative sample (Kim et al., 2015). Another factor 
is that the tissue samples theoretically include bacteria in the tissue epithelium and sinus 
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mucosa (Kim et al., 2015). After ESS, patients were encouraged to use nasal irrigation. This 
irrigation may have impacted the swab samples' composition as it might wash away bacteria 
on the mucosa that were not contained in a biofilm.  
Unlike alpha and beta diversity, tissue and swab samples' taxonomic compositions were 
similar for most patients (Figure 3.10). Both sample types were composed primarily of the 
same genera (Staphylococcus, Dolosigranulum, and Corynebacterium) with some variation in 
relative abundance. Tissue and swab samples exhibited different compositional patterns in 
some patients, such as patient 10, where the relative abundance of Staphylococcus and 
Moraxella differed between swab and tissue samples. Swab and tissue samples for patient 2 
also differed as there was a wider diversity of genera present in the tissue samples. Patient 2’s 
sinonasal microbiome was composed primarily of Staphylococcus, which could have formed a 
biofilm, protecting the other genus observed in the tissue (Hayes et al., 2015; Kim et al., 2015). 
Interestingly, Staphylococcus was typically found in higher relative abundance in swab 
samples. Bassiouni et al. (2015) also found Staphylococcus at a higher relative abundance in 
swab samples; however, the cause of this difference is unknown. 
Overall, this study showed that the microbiome of swab and tissue samples were 
broadly similar but distinct. It should be noted that although tissue samples appeared to capture 
a greater bacterial diversity, this type of sample collection is invasive and logistically 
challenging. Our study, along with Bassiouni et al. (2015) and Kim et al. (2015), collected 
tissue samples during ESS; however, swab samples can be easily collected in a clinic rather 
than during surgery. This makes swab samples less invasive and therefore more viable for 
studies not involving surgery. Future studies may wish to investigate alternative, less invasive 
methods to collect samples from the sinuses that also collects cells from the epithelium. This 
type of sampling would allow the biofilms and bacteria present in the epithelium to be sampled, 
along with the microorganisms present in the nasal mucosa. This is important due to the current 
hypothesis that biofilms may play a role in the maintenance or pathogenesis of CRS (Fokkens 
et al., 2012; Hayes et al., 2015; Wood & Douglas, 2010).  
 
4.2 The placebo treatment had better clinical outcomes than the 
antibiotic treatment 
Over the past few years, there has been a push in the medical community to reduce the 
use of unnecessary antibiotics. In response, several studies have been conducted to investigate 
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whether post-operative antibiotics improve surgical outcomes in CRS patients undergoing ESS 
(Albu & Lucaciu, 2010; Jiang et al., 2008; Lehmann et al., 2020; Liang et al., 2011). Albu and 
Lucaciu (2010) investigated the effects of post-operative antibiotics after ESS on 75 patients 
in a randomised, double-blind, placebo-control study. This study found that patients who 
received antibiotics had better endoscopic outcomes during the blood crust healing phase (days 
5-12), along with better patient scores for nasal obstruction and drainage (Albu & Lucaciu, 
2010). Jiang et al. (2008) investigated the efficacy of the post-operative use of 
amoxicillin/clavulanate after ESS for 71 patients in a randomised placebo-control study and 
found that amoxicillin/clavulanate did not improve the short-term outcomes of ESS for 
endoscopic or symptom scores (Jiang et al., 2008). Lehmann et al. (2020) assessed the impact 
of post-operative use of amoxicillin/clavulanate after ESS on 77 patients in a randomised, 
double-blind, placebo-control, noninferiority trial. No significant difference in the quality of 
life, endoscopic scores, or infection rate were observed, but the authors did observe a higher 
percentage of side effects in patients who received antibiotics (Lehmann et al., 2020). Liang et 
al. (2011) examined the efficacy of Chinese herbal medicine, amoxicillin, and a placebo, on 97 
patients in a randomised, double-blind, placebo-control study. This study observed no benefit 
for patients' symptoms or endoscopic scores when using Chinese herbal medicine or 
amoxicillin, as these treatments recorded similar results to the placebo group (Liang et al., 
2011). Corroborating these earlier studies, our results provided additional clinical evidence to 
show that there is no significant difference in short-term surgical outcomes between patients 
who receive a placebo or antibiotics.  
In our study, all but one patient reported improved symptoms according to the pre-
operative and three-month post-operative SNOT-22 scores (Figure 3.1). The difference 
between the SNOT-22 scores pre- and post-operatively was significant (p-value = 0.0002). The 
radiological and endoscopic scores also showed an improvement in the sinuses' appearance 
after the surgery (Figure 3.3). Our results were similar to previous research, indicating that ESS 
successfully treated CRS short-term for most patients (Jain et al., 2018; Terris & Davidson, 
1994). 
Interestingly, although most patients show a difference between the pre- and post-
operative clinical results, our results showed no significant difference in the clinical outcomes 
between antibiotic and placebo treatment groups. There was a weak trend that may indicate 
better SNOT-22 scores after ESS for the placebo treatment (Figure 3.2), noting that our study 
had a modest sample size and was statistically underpowered. Both the radiological and 
endoscopic scores for patients receiving antibiotics or placebos were similar. These findings 
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corroborate Jiang et al. (2008), Lehmann et al. (2020), and Liang et al. (2011), which all found 
no significant difference between antibiotic and placebo treatment for CRS patients undergoing 
ESS. In contrast, Albu and Lucaciu (2010) found that antibiotics were associated with better 
surgical outcomes, specifically for discharge and nasal obstruction symptoms, and endoscopic 
score results.  
Although this study did not find any significant difference in clinical outcomes between 
treatment groups , there was a difference regarding patients' reported side effects (Table 3-2). 
Half of the patients who received antibiotics reported side effects, while one patient who 
received the placebo medication reported side effects. This side effect appeared to be due to 
this patient having a throat infection (unlikely to be related to ESS). This increase in reported 
side effects corroborates results in Lehmann et al. (2020), which also showed a higher 
percentage of patients receiving antibiotics reporting side effects. The increase in side effects 
suffered by patients receiving antibiotics should be considered when determining if post-
operative antibiotics should be encouraged. Previous studies, except Lehmann et al. (2020), 
did not consider the side effects (Albu & Lucaciu, 2010; Jiang et al., 2008; Liang et al., 2011).  
 
4.3 ESS surgery alters the sinonasal microbiome over time  
The bacterial communities examined in this study were composed primarily of 
Staphylococcus, Dolosigranulum, and Corynebacterium (Figure 3.29, Figure 3.30, and Figure 
3.31). Staphylococcus and Corynebacterium were identified in previous studies as the 
dominant genera in the sinonasal microbiome, while Dolosigranulum is only identified in some 
studies (Cope et al., 2017; Hoggard, Biswas, et al., 2017; Jain et al., 2017). Although the 
reported bacterial compositions in our study are similar to previous research, our data showed 
a less diverse microbiome for most samples (Cope et al., 2017; Hoggard, Biswas, et al., 2017; 
Jain et al., 2017). Some patients in previous studies had a similar diversity to this study, but the 
inter-individual variation for the microbial composition is more evident in previous research 
(Hoggard, Biswas, et al., 2017; Jain et al., 2018). The phylum-level composition was similar 
to previous studies [data not shown] (Cope et al., 2017; Hoggard, Biswas, et al., 2017; Jain et 
al., 2017). This difference in taxonomic composition may have been due to our modest sample 
size or differences in the PCR primers used in our study. Cope et al. (2017) and our study 
sequenced the V4 region of the 16S rRNA gene, whereas Jain et al. (2017) and Hoggard, 
Biswas, et al. (2017) sequenced the V3-V4 regions of the 16S rRNA gene.  
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There was no statistically significant difference for alpha and beta diversity between 
treatments (Figure 3.21 and Figure 3.22). These results indicated that the antibiotics did not 
significantly impact the microbial diversity. Interestingly, although there was no statistical 
difference between the treatment groups after surgery (T2 and T3), Adonis2 analysis showed 
a significant difference between the two treatment groups prior to surgery and medication (T1) 
(p-value = 0.008). The difference in alpha diversity between the treatment groups at T1, 
however, was not significant. At T1, placebo samples had a higher relative abundance of 
Staphylococcus, whereas the antibiotic samples had a higher abundance of Corynebacterium 
(Figure 3.29). This shift in diversity after T1 is most likely due to the surgery itself rather than 
any post-operative medication since there was no statistically meaningful difference in beta 
diversity between treatments at T2 and T3. Intravenous antibiotics administered during the ESS 
in all patients may account for the observed change in diversity. A previous study investigating 
the post-operative microbiome of CRS patients indicated that post-operative antibiotics were 
ineffective at eliminating microbes in the sinonasal microbiome as the local flora were still 
present in the microbiome of patients treated with post-operative antibiotics (Hauser et al., 
2016).  
Both treatments showed an increase in alpha diversity over time (Figure 3.32 and Figure 
3.34). The alpha diversity of the placebo treatment showed a significant difference between the 
T1 and T3 time points (p-value = 0.046). In contrast, the antibiotic treatment did not show a 
significant relationship (p-value = 0.217). This suggests that the placebo treatment had a more 
significant increase in richness compared to the antibiotic treatment. Previous studies found 
that ESS was associated with an increase in richness (Hauser et al., 2016; Jain et al., 2017), but 
it is unknown whether this increase in diversity is associated with improved clinical outcomes. 
However, evidence generally suggests that a more diverse microbiome is associated with better 
health (Pflughoeft & Versalovic, 2012; Ramakrishnan et al., 2016). This suggests that ESS may 
help improve clinical outcomes through facilitating a more diverse microbiome; however, the 
mechanics behind this increase in diversity is unknown. Our findings indicate that antibiotics 
may inhibit an increase in diversity and that patients who received the placebo had better 
outcomes on the basis of sinonasal microbial community richness.  
The taxonomic composition for both treatments showed an increase in Staphylococcus 
and a decrease in Corynebacterium in most samples after the surgery (Figure 3.29, Figure 3.30, 
and Figure 3.31). This trend has previously been reported by Jain et al. (2017). Previous 
research linked S. aureus to an increased risk in revision surgery and a more recalcitrant disease 
(Cleland et al., 2013). The increase in the relative abundance of Staphylococcus did not 
68 
 
significantly link to worse surgical outcomes in Jain et al. (2017) and our study. It should be 
noted, however, that the one patient who had worse clinical outcomes (patient 4) also showed 
a significant increase of Staphylococcus at the T3. Corynebacterium, which decreased in the 
T3 samples, is associated with a diseased state and worse symptom scores (Anderson et al., 
2016; Jain et al., 2017). This decrease in Corynebacterium could be linked to improved clinical 
outcomes in this study; however, further research into the relationship between clinical 
outcomes and these genera is needed before conclusive statements can be made.  
Our study provides evidence that ESS can change patients' microbial composition and 
may lead to an increase in richness. The exact reason for these changes is unknown; however, 
antibiotics administered during ESS or sinus structure may play a role. This study found no 
significant difference between patients who did/did not receive antibiotics, so post-operative 
antibiotics use is unlikely to play a significant role in changing the microbiome. It should be 
noted that there was a general trend of increased richness in the placebo group compared to the 
antibiotic group (Figure 3.23, Figure 3.24, and Figure 3.25); however, our study was 
underpowered due to the modest sample size. Other factors that may account for this change 
in the sinonasal microbial composition include physical change in the sinus structure and 
associated increased airflow. Increased airflow may lead to a change in the nasal conditions 
leading to a microbiome change. Our findings potentially indicate that it is more beneficial not 
to have post-operative antibiotics.  
 
4.4 Relationship between clinical variables and the sinonasal 
microbiome  
Asthma appeared to affect the pre-ESS sinonasal microbial composition (Figure 3.14). 
The alpha diversity in swab samples for patients with/without asthma was significantly 
different (p-value = 0.026), and Adonis2 analysis showed notable differences for both tissue 
and swab samples (p-value = 0.005 and 0.056, respectively). Corynebacterium or 
Dolosigranulum dominated the sinonasal microbiome of patients without asthma, whereas 
Staphylococcus appeared associated with asthma (Figure 3.14 and Figure 3.15). Asthma has 
been shown to influence the lung microbiome (Mahdavinia et al., 2016) and has previously 
been associated with the variability of the microbiome in CRS patients undergoing ESS (Jain 
et al., 2017). Analysis of CRS patients with/without asthma has shown a significant difference 
in the sinonasal microbial composition (Ramakrishnan et al., 2015). Asthma is a disease 
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characterised by chronic inflammation of the respiratory system (Mahdavinia et al., 2016). This 
inflammatory response may be associated with the microbiome, which may explain some 
differences observed between the microbiome of patients with/without asthma (Mahdavinia et 
al., 2016). Although this disease may influence the microbiome, it is unknown what impact 
this has on clinical outcomes, and due to our modest sample size, this could not be investigated 
in greater detail.  
Nasal polyps were also investigated; however, they were not found to impact the 
sinonasal microbiome significantly. Hauser et al. (2016) and Ramakrishnan et al. (2015) also 
found that nasal polyps' presence did not significantly correlate with microbial community 
composition. This result was interesting since there is some evidence that CRS with/without 
nasal polyps are different CRS subtypes (Yang et al., 2015), and there has been evidence 
suggesting that CRSwNP has a different inflammatory response (Yang et al., 2015). 
Nevertheless, our results indicate that the microbiome for patients with/without nasal polyps 
were similar in both tissue and swab samples.  
Both asthma and nasal polyps are associated with inflammatory conditions but have 
different aetiology. Asthma was the only recorded clinical condition to significantly correlate 
with differences in the microbial communities in our study; this may be due to 
CRSwNP/CRSsNP having some overlapping features (Lam et al., 2015; Yang et al., 2015). 
Further analysis of the effects of these conditions on the microbiome and the effect on the 
clinical outcomes of ESS should be investigated using a more targeted sampling design and 
large sample sizes. 
 
4.5 Limitation of this study 
There were some limitations to our study. First, our study is preliminary and 
consequently has a modest sample size. This means that there is very limited statistical power 
for many of the analyses. A large study is needed to strengthen and further investigate the 
observations made in this study. Patients in our study were not a priori separated into groups 
according to their clinical state, i.e., CRSwNP, asthma, etc. Although these clinical factors may 
influence the microbiome, as seen in asthma patients, they were not specifically targeted by 
our study design, and our observations were limited by small sample sizes. Another limitation 
was inconsistent timing of the T3 samples due to the COVID-19 lockdown, which led to some 
patients having their T3 samples collected after six months, compared with six weeks for other 
patients. This may have impacted taxonomic composition and alpha diversity since some 
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patients had longer for their sinonasal microbiome to recover from the surgery or antibiotics. 
Finally, this study is only a short-term study and does not account for revision surgery, nor 




5 Chapter Five: Conclusions and Future Directions 
The aim of this study was to investigate the effects of post-operative antibiotics on the 
sinonasal microbiome and clinical outcomes in CRS patients undergoing ESS. Our study also 
compared the microbial composition of swab and tissue samples collected from the sinuses to 
determine whether swab samples had similar microbial compositions to tissue samples. The 
findings of our study revealed that tissue and swab samples had distinct but broadly similar 
sinonasal microbiomes. Our study found no significant difference between patients who 
received the antibiotic treatment and those who received the placebo. The clinical results 
(SNOT-22 and LMS/MLMES) showed no significant difference between the treatments before 
or after ESS; however, patients who received the antibiotic treatment had a higher risk of side 
effects. The placebo treatment also showed a lower SNOT-22 and MLMES on average; 
however, this difference was not statistically significant. There was no significant difference 
in the post-ESS sinonasal microbiome of antibiotic and placebo treatment groups. The results 
of our study found that the alpha diversity significantly increased over time for placebo 
treatments, while the beta diversity and composition for both treatments did not significantly 
differ across the T2 and T3 samples. The T1 samples showed significant differences between 
the treatment groups according to the beta diversity analyses. Overall, our results showed that, 
in the short term, there is no significant clinical or sinonasal microbial difference between 
patients who received placebo and antibiotics. This may indicate that there is no demonstrable 
need for post-operative antibiotics unless the patient shows symptoms of post-operative 
infection. Furthermore, post-operative antibiotics may be associated with negative outcomes 
such as reduced alpha diversity and increased risk of side effects. It should be noted that our 
study is underpowered due to the modest sample size, and a more extensive study could expand 
on the hypothesis that antibiotics have a detrimental impact on CRS patients recovering from 
ESS. 
A more extensive study could account for clinical variables such as asthma, which our 
study was unable to do due to its modest sample size.  A larger study could further analyse the 
relationship between the treatment groups and expand on the difference observed in alpha 
diversity between the treatment groups. Along with further antibiotic trials, another study 
investigating sampling techniques could give further insight into what sampling method is ideal 
for sinonasal microbiomes studies and allow for standardised protocols in this field. A study 
comparing cytology brush samples to tissue and swab samples should be considered as the use 
of a cytology brush as a sampling method may allow for the first layers of epithelium and 
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biofilms to be collected. A cytology brush might exhibit a similar microbial ecology to a tissue 
sample, however, be less invasive to collect as it would not require surgery. Finding the best 
sampling method for sinonasal microbiome studies would allow for more comparable results 
between the different studies and reduces the variables needed to be considered when making 
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6.1 Supplementary material for chapter two 
Sample  input filtered denoisedF denoisedR merged nonchim 
001_1_TR 147193 121964 118219 118262 104249 76219 
001_1_TL 98510 79999 79312 79336 75927 37540 
001_1_SR 100213 81094 80442 80453 75405 44612 
001_1_SL 91844 78987 78299 78379 74322 40465 
001_2_SR 28753 17572 16934 17102 14085 9829 
001_2_SL 190668 161898 156751 156986 142743 103714 
001_3_SR 125660 101370 99939 100092 93290 53354 
001_3_SL 94821 75051 73289 73597 68260 38744 
002_1_TR 197362 166213 162302 161904 146674 109135 
002_1_TL 178750 153213 148804 148484 136189 100943 
002_1_SR 74181 57587 54994 55251 48393 31345 
002_1_SL 175356 150326 148296 148401 139320 96164 
002_2_SR 108092 91497 90004 90513 83010 58713 
002_2_SL 95656 79791 79323 79511 78112 37784 
002_3_SR 148222 126083 121565 120551 108428 78515 
002_3_SL 113552 91490 86496 85749 74610 51869 
003_1_TR 95574 76248 71793 72564 61580 47561 
003_1_TL 87509 71974 70740 70784 65245 42216 
003_1_SR 51436 38426 37022 37160 34205 22216 
003_1_SL 76805 63417 62573 62629 58205 36213 
003_2_SR 79321 64456 63738 63929 61106 38253 
003_2_SL 90661 75407 74216 74369 71399 44739 
003_3_SR 82141 68174 67688 67740 65159 39691 
003_3_SL 14079 11710 11511 11606 10754 7070 
004_1_TR 142195 119638 119367 119347 110261 79110 
004_1_TL 139693 118383 116444 116855 107554 66886 
004_1_SR 111708 89060 88792 88911 84818 46563 
004_1_SL 96159 81351 80987 81112 78132 41019 
004_2_SR 74105 61914 61383 61335 56371 36994 
004_2_SL 98658 85945 85581 85524 83698 49335 
004_3_SR 93786 78211 77002 76767 72997 45702 
004_3_SL 99129 81434 80581 80572 77274 43263 
005_1_TR 112161 94757 94387 94391 91429 54658 
005_1_TL 195958 167838 166750 166801 157484 90476 
005_1_SR 100269 82123 81730 81961 79516 37978 
005_1_SL 102661 86580 86059 86306 82308 27933 
005_2_SR 167985 139476 138765 138717 131340 85031 
005_2_SL 206311 177492 174453 174970 159422 112287 
005_3_SR 128356 112320 111668 111703 107026 58281 
005_3_SL 85951 74353 74039 73992 72126 34942 
82 
 
006_1_TR 133400 108827 106485 106664 94691 65563 
006_1_TL 187282 161163 159634 160036 146030 104513 
006_1_SR 137091 115429 113769 113862 103072 74535 
006_1_SL 254034 227155 226033 226370 211719 153792 
006_3_SR 132160 112504 111220 111380 105308 68789 
006_3_SL 194840 162541 161589 161808 154332 81971 
007_1_TR 192886 167060 165748 165934 152882 106611 
007_1_TL 147137 126518 125688 125685 116805 69201 
007_1_SR 90764 73957 72821 73221 66640 46866 
007_1_SL 115257 92665 90693 91180 82072 44007 
007_2_SR 63369 48218 46886 47128 42075 26774 
007_2_SL 91438 72118 70349 70065 60945 38134 
007_3_SR 96842 78692 77254 77522 70457 47113 
007_3_SL 86658 69640 68831 68979 63012 37043 
008_1_TR 130932 111669 108363 107543 94686 70637 
008_1_TL 85539 72088 70610 70632 62907 40360 
008_1_SR 125466 104618 103363 103546 95098 58590 
008_1_SL 114442 98231 97069 97218 91633 54754 
008_2_SR 84003 67844 64420 64684 57418 36515 
008_2_SL 95737 80516 78130 78188 69560 46912 
008_3_SR 145689 123169 122267 122192 114073 77687 
008_3_SL 106000 86668 85383 85363 78346 45433 
009_1_TR 181347 158665 155890 155988 143595 104381 
009_1_TL 111407 97301 94063 94352 85805 59313 
009_1_SR 97406 73628 72554 72899 68011 36111 
009_1_SL 110272 95426 93638 94096 87255 57013 
009_2_SR 81434 67966 65086 65387 57251 40775 
009_2_SL 98177 85221 82970 83296 76059 51035 
009_3_SR 95228 83569 82348 82441 77355 45970 
009_3_SL 85371 75828 74813 74946 72366 36636 
010_1_TR 95371 83141 80858 81061 73663 52180 
010_1_TL 77351 68232 66586 67080 60045 43916 
010_1_SR 137523 117218 116468 116471 109747 73000 
010_1_SL 123311 108082 107568 107437 101363 58570 
010_2_SR 117443 93396 91735 91868 82870 53245 
010_2_SL 106463 90153 88663 88925 80901 54561 
010_3_SR 4155 3418 3390 3389 3360 2103 
010_3_SL 1866 719 629 646 109 87 
011_1_TR 712 256 213 217 212 212 
011_1_TL 1199 232 156 163 147 147 
011_1_SR 190691 165676 162723 162983 150706 112825 
011_1_SL 145283 122453 121462 121168 115073 73033 
011_2_SR 110669 90533 90322 90270 86564 55378 
011_2_SL 24122 20312 20196 20243 19263 11252 
011_3_SR 315 166 146 116 22 22 
011_3_SL 293 138 113 90 22 0 
83 
 
012_1_TR 263 142 117 100 14 0 
012_1_TL 209 107 92 63 0 0 
012_1_SR 112156 89605 88888 89207 81712 54050 
012_1_SL 167093 130062 129229 129469 111933 64232 
012_2_SR 62172 52235 50078 50358 43459 32006 
012_2_SL 915 235 189 177 0 0 
012_3_SR 193 66 48 42 0 0 
012_3_SL 207 72 44 37 0 0 
C_21/11/19 122987 87975 87515 87259 82443 39596 
C_05/12/19 185622 146128 145493 145258 140047 70983 
C_06/12/19 65499 40242 39958 39758 37116 18641 
C_19/12/19 87365 62376 61940 61952 59132 33397 
C_21/12/19 124806 91657 91072 90623 85606 38653 
C_11/01/20 199524 162303 161192 161756 155266 91592 
C_24/01/20 128095 101970 101648 101230 98591 57475 
C_12/03/20 57825 42462 42368 42080 40800 17508 
C_21/03/20 50949 34535 34324 33721 32117 20244 
C_05/06/20 27763 21286 20778 20767 19693 11279 
C_12/06/20 88069 59414 59153 59138 56991 36855 
C_26/06/20 127127 101703 100999 100390 94541 45080 
C_10/07/20 146023 113234 112805 112357 108538 56618 
C_17/07/20 124475 102073 101773 101533 98515 56803 
C_31/07/20 110563 90412 89916 89426 83793 40747 
C_14/08/20 66805 53140 52905 52491 49965 26486 
C_18/09/20 130943 99380 99030 98699 95774 50917 
C_02/10/20 108429 84298 83634 83661 78901 43203 
C_09/10/20 75181 54272 54072 53931 52650 24159 
C_16/10/20 125426 98282 97740 97572 93072 46562 
C_23/10/20 134929 106389 105957 105117 100842 52878 
C_11/11/20 161103 130617 128124 128221 114622 64798 
PCR_pos 145425 53697 52476 52651 51256 35150 
PCR_neg 44443 32617 31967 32007 22892 7068 







6.2 Supplementary material for chapter three 
Sample Observed Richness Shannon Breakaway Estimates 
001_1_TR 299 4.54 326.07 
001_1_TL 262 4.71 274.09 
001_1_SR 214 4.77 215.00 
001_1_SL 187 4.68 188.07 
001_2_SL 362 4.91 417.12 
001_3_SR 302 5.07 319.76 
001_3_SL 296 4.97 302.22 
002_1_TR 287 4.32 345.09 
002_1_TL 230 4.08 291.20 
002_1_SR 301 5.14 307.35 
002_1_SL 198 4.59 227.26 
002_2_SR 178 4.78 178.01 
002_2_SL 122 4.41 122.00 
002_3_SR 345 4.49 390.07 
002_3_SL 383 5.08 405.13 
003_1_TR 188 4.17 207.11 
003_1_TL 225 4.92 234.13 
003_1_SL 236 4.90 260.09 
003_2_SR 181 4.36 182.03 
003_2_SL 187 4.38 192.08 
003_3_SR 146 4.49 152.46 
004_1_TR 148 3.76 152.00 
004_1_TL 202 4.81 215.05 
004_1_SR 171 4.74 172.00 
004_1_SL 189 4.78 190.01 
004_2_SR 202 4.75 203.02 
004_2_SL 138 3.93 139.00 
004_3_SR 227 4.73 231.03 
004_3_SL 235 4.96 243.06 
005_1_TR 136 4.33 139.02 
005_1_TL 288 4.96 296.15 
005_1_SR 171 4.64 171.00 
005_1_SL 192 5.01 192.25 
005_2_SR 205 4.70 214.02 
005_2_SL 271 4.42 323.94 
005_3_SR 184 4.82 189.03 
005_3_SL 219 4.95 220.25 
006_1_TR 292 4.51 310.09 
006_1_TL 215 4.12 225.03 
006_1_SR 191 3.92 204.06 
006_1_SL 138 3.61 155.02 
006_3_SR 218 4.47 223.04 
006_3_SL 347 5.28 350.01 
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007_1_TR 320 4.68 329.03 
007_1_TL 226 4.33 229.00 
007_1_SR 219 4.55 230.70 
007_1_SL 236 4.69 238.04 
007_2_SR 269 5.20 267.01 
007_2_SL 303 5.30 309.55 
007_3_SR 236 4.77 239.02 
007_3_SL 249 5.04 249.00 
008_1_TR 215 4.19 231.09 
008_1_TL 173 4.65 174.01 
008_1_SR 269 4.93 273.01 
008_1_SL 170 4.66 178.04 
008_2_SR 246 5.03 253.03 
008_2_SL 374 5.27 386.10 
008_3_SR 276 4.62 289.07 
008_3_SL 324 5.27 330.02 
009_1_TR 241 4.15 259.08 
009_1_TL 217 4.57 236.11 
009_1_SR 200 4.63 203.01 
009_1_SL 217 4.65 223.01 
009_2_SR 252 4.84 259.06 
009_2_SL 245 4.97 254.05 
009_3_SR 220 4.76 227.06 
009_3_SL 160 4.65 162.03 
010_1_TR 274 4.95 294.10 
010_1_TL 126 4.12 132.05 
010_1_SR 213 4.69 222.04 
010_1_SL 184 4.53 190.25 
010_2_SR 293 5.04 297.00 
010_2_SL 225 4.76 232.07 
Table 6-2: Alpha diversity data for each sample. Observed richness and Shannon indices were calculated using rarefied 
data while breakaway estimates were made using unrarefied data. 
 
